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Zusammenfassung 
Hypertrophische Kardiomyopathie (HCM) ist eine Erkrankung des Herzmuskels, die durch 
linksventrikuläre Hypertrophie und unregelmäßige Anordnung der Herzmuskelzellen 
charakterisiert ist. Eine sehr häufige Ursache der autosomal dominant vererbten HCM sind 
Punktmutationen in der schweren Kette des !-Myosins (!-MHC), welches außer im Myokard 
auch in langsamer Skelettmuskulatur exprimiert wird. Überraschenderweise fanden wir bei 
Quantifizierung des Anteils mutierter !-MHC in Biopsien des M. soleus von HCM-Patienten 
signifikante Abweichungen von dem aufgrund des Erbgangs erwarteten 50:50-Verhältnis von 
Wildtyp- zu mutierter !-MHC. Eine erste Quantifizierung des Anteils mutierter !-MHC-
mRNA ergab für eine Mutation auch eine ähnliche Abweichung auf mRNA-Ebene. In der 
vorliegenden Arbeit wurde untersucht, ob es auch bei anderen !-MHC-Mutationen eine 
Abweichung vom Verhältnis 50:50 gibt und ob im M. soleus und im Myokard von HCM-
Patienten eine vergleichbare Abweichung vorliegt. Um den der Abweichung zugrunde 
liegenden Mechanismus zu erforschen, wurde überprüft, ob bei Geschwistern, bei Patienten 
verschiedener Generationen der gleichen Familie und bei nichtverwandten Patienten mit der 
gleichen Mutation die Abweichung vom 50:50 Verhältnis ähnlich ist.  
Um mögliche Artefakte durch Bildung von Heteroduplexen aus einem Wildtyp und einem 
mutiertem DNA-Strang zu minimieren und sichere Aussagen über das Verhältnis von 
Wildtyp- zu mutierter !-MHC-mRNA machen zu können, wurde eine besondere PCR-
Methode mit einem Rekonditionierungsschritt entwickelt. Die Methode basiert auf reverse-
transcription PCR mit nachfolgender PCR und rekonditionierender PCR. Quantifizierung 
erfolgt durch enzymatischen Verdau und Restriktions-Fragment-Analyse. 
Die Ergebnisse zeigten, dass der Anteil an mutierter !-MHC-mRNA bei Patienten mit der 
I736T-Mutation 38.4±7.6% und bei Patienten mit der R723G-Mutation 67.2±3.3% beträgt. 
Die Abweichung vom 50:50-Verhältnis war sehr ähnlich unter Geschwistern (I736T: 37.6%, 
39.1% und 38.6%; R723G: 66.4% und 62%). Darüber hinaus fanden wir sowohl bei HCM-
Patienten einer jüngeren Generation und aus einer anderen Familie mit der Mutation R723G, 
wie auch im Myokard von zwei Patienten mit dieser Mutation etwa den gleichen Anteil 
mutierter !-MHC-mRNA (71.8% und 67.2% im Myokard, 69.6% und 66.1% im M. soleus). 
Diese Daten, die auch durch ähnliche Beobachtungen an zwei nichtverwandten HCM-
Patienten mit der Mutation V606M unterstützt werden, zeigen, dass der Anteil mutierter !-
MHC-mRNA im langsamen Skelettmuskel und im Myokard etwa gleich ist, und typisch für 
die jeweilige Mutation zu sein scheint. Interessanterweise beobachteten wir bei den Familien 
eine Korrelation zwischen Schweregrad der Erkrankung und Anteil mutierter !-MHC-mRNA 
bzw. !-MHC im Muskel. Dies bedeutet, dass das Verhältnis von Wildtyp- zu mutiertem 
Protein im Myokard der Patienten zur Heterogenität des HCM-Phänotyps beitragen könnte.  
Funktionelle Untersuchungen in unserer Gruppe und erste mRNA-Quantifizierung in 
einzelnen Skelettmuskelfasern von HCM-Patienten in der vorliegenden Arbeit deuten auf 
eine variable Expression der !-MHC-mRNA von Faser zu Faser und damit auf einen 
variablen Anteil an mutierter !-MHC in den Sarkomeren dieser Fasern hin. Um dies in 
Zukunft weiter untersuchen zu können haben wir eine neue Methode zur relativen mRNA-
Quantifizierung in viel kleineren Gewebeproben, bis hin zu einzelnen Myokardzellen, 
etabliert, die auf einem Pyrosequenzier-Verfahren basiert. Ein variabler Anteil mutierter !-
MHC von Zelle zu Zelle würde zu einem funktionellen Ungleichgewicht zwischen den 
Herzmuskelzellen führen und könnte so die Entstehung von „disarray“ und anderen 
Charakteristika des HCM-Phänotyps auslösen. 
Abstract 
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Abstract 
 
Hypertrophic Cardiomyopathy (HCM) is a myocardial disease characterized by left 
ventricular hypertrophy and myocyte disarray. The disease is transmitted in an autosomal 
dominant manner. Mutations in genes encoding different sarcomeric proteins have been 
found as cause of HCM. Missense mutations in the !-myosin heavy chain (!-MHC), which is 
the MHC of ventricular myocardium and slow skeletal muscle like M. soleus, account for 
nearly 40% of all genetically characterized HCM cases. Our group found, unexpectedly, that 
in soleus muscle biopsies of HCM patients, heterozygous for !-MHC mutations, the ratio of 
wildtype vs. mutated !-MHC deviated significantly from the expected 50:50 ratio. In 
preliminary work, quantification of the fraction of mutated !-MHC-mRNA showed a similar 
deviation for one mutation also at the mRNA level. Here we investigated whether a deviation 
from the 50:50 relation is also found for other !-MHC mutations and whether it is similar in 
biopsies of slow skeletal muscle and myocardium of HCM patients. Since the underlying 
mechanism for development of the deviation is unclear, we also studied whether the 
deviation is similar in HCM patients of the same family of different generations and of 
unrelated families with that mutation.  
To ensure that quantification with the previously used restriction digest method is not 
falsified by artifacts like formation of heteroduplexes of one wildtype and one mutant DNA 
strand in PCR at high cycle numbers, a ‘reconditioning PCR’ method was established. The 
method is based on reverse-transcription polymerase chain reaction (RT-PCR) followed by 
PCR and a reconditioning PCR step to ensure that no heteroduplexes underwent the 
subsequent enzymatic cleavage of the PCR products and restriction fragment analysis.  
We found that for patients with the !-MHC mutations I736T and R723G the fraction of 
mutated !-MHC-mRNA in the samples studied on average was 38.4±7.6% and 67.2±3.3%, 
respectively. The deviation from 50% was found to be quite similar for siblings (I736T: 
37.6%, 39.1% and 38.6%; R723G: 66.4% and 62%). Furthermore, essentially the same 
fraction of mutated !-MHC-mRNA was also found in younger family members, in an 
unrelated family also with the R723G mutation, as well as in myocardium of two patients 
with this mutation (71.8% and 67.2% for myocardium, 69.6% and 66.1% for soleus, 
respectively).  
These data, which are confirmed by similar findings for two unrelated patients with mutation 
V606M, indicate that the level of expression of the mutated !-MHC mRNA for each 
mutation not only is essentially the same in slow skeletal muscle and in myocardium but also 
appears to be characteristic of each mutation. Interestingly, for the families studied the 
malignancy of the disease is correlated with the fraction of mutated !-MHC-mRNA and !-
MHC in the muscle tissue, which may indicate that the expression level of a mutation 
contributes to the heterogeneity of the HCM phenotype. 
Functional studies in our group and preliminary mRNA quantifications in this work on single 
slow muscle fibers indicate a variable expression of mutated !-MHC-mRNA from fiber to 
fiber and hence a variable amount of mutated !-MHC in these fibers. To test this in the future 
we established a new method for relative mRNA quantification in much smaller samples, 
possibly even single cells, using a pyro-sequencing approach. A variable proportion of 
mutated !-MHC from cell to cell is expected to cause functional imbalances among the 
cardiomyocytes, and may thereby trigger the development of cardiomyocyte disarray and 
other features characteristic for the HCM phenotype. 
Abstract 
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1 Abbreviations 
"-MHC                   alpha myosin heavy chain 
APS        Adenosine 5’ phosphosulfate 
!-MHC         beta myosin heavy chain 
bp         base pair 
BSA       bovine serum Albumin 
CCD        Charge coupled device 
cDNA       complementary deoxyribonucleic acid 
dATPaS        Deoxyadenosine alpha thio-triphosphate 
dNTP       deoxyribonucleotide tri-phosphate 
DTT        Dithiothreitol 
ECG        Electrocardiogram 
EDTA            Ethylene diamine-N, N, N’, N’ tetra acetic acid 
ELC         Essential Light Chain 
EtBr        Ethidium Bromide 
G              Glycine 
GSP          Gene Specific Primer 
HCM        Hypertrophic Cardiomyopathy 
I         Isoleucine 
ICD       Implantable Cardioverter Defibrillator 
IOD       Integrated Optical Density 
KDa       Kilo Dalton 
M           Methionine 
mg          milligram 
min         minute 
ml           milliliter 
"l            microliter 
mm         millimeter 
Mut          Mutant/mutated 
MYBPC3    Cardiac Myosin Binding Protein C 
MYH7       Myosin Heavy chain 
NYHA     New York Heart Association 
Abbreviations 
11 
PCR       Polymerase Chain Reaction 
Pi           inorganic phosphate 
PPi          pyrophosphate 
Q           Glutamine 
R           Arginine 
RLC         Regulatory Light Chain 
RT          Reverse Transcription 
RTase       Reverse transcriptase 
SNP         single nucleotide polymorphism 
T        Threonine 
TBE         Tris, Boric acid, EDTA 
TNNI3          Cardiac Troponin I 
TNNT2   Cardiac Troponin T 
V          Valine 
W       Tryptophan 
WT        Wild Type 
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2 Introduction 
 
 
2.1 The human heart and Hypertrophic Cardiomyopathy 
The human heart is one of the most efficient pumps known. This organ, composed entirely of 
involuntary muscles called myocardium, in a normal condition, pumps blood between two 
independent systems, the pulmonary and the systemic circulations, respectively. During 
cardiac relaxation or ‘diastole’, the ventricular chambers get filled with blood from the atria; 
the right ventricle with deoxygenated blood and the left ventricle with oxygenated blood. 
During the contractile phase or ‘systole’, the left ventricle pumps blood into the various parts 
of the body and the deoxygenated blood in the in the right ventricle is pumped via the 
pulmonary artery into the lungs where it can be oxygenated again (Guyton and Hall, 1998).  
Impairments in the systolic or diastolic functions may lead to a chronic disorder called heart 
failure. As a root cause of heart failure are always one or a series of abnormalities such as 
valve disease, congenital malformations, rhythm disturbances or cardiomyopathies (Ahmad 
et al., 2005). These ‘initiating insults’ lead to an overall morphological remodeling and 
hemodynamic changes.  
 
Hypertrophic Cardiomyopathy (HCM), also known by other names such as idiopathic 
subaortic hypertrophic stenosis or hypertrophic obstructive cardiomyopathy, as the name 
suggests, is a disease of the cardiac muscle. In 1957 HCM was described for the first time by 
Sir Russell Brock, who found a functional subvalvular obstruction in patients undergoing 
corrective surgery for aortic stenosis. In 1958 came a description from D. Teare, who 
described asymmetric septal hypertrophy with bizarre muscle bundle orientations in the 
hearts of 8 patients who died suddenly. It was only in the 1960s when Braunwald and 
colleagues reported a disease condition in which asymmetric septal hypertrophy, myofibrillar 
disarray and dynamic outflow tract obstruction were encountered.  
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a
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A B
 
 
Fig. 1. The morphological remodeling of the heart in HCM. A normal heart (B) and a 
hypertrophic heart (A). The reduction in the left ventricular (LV) chamber volume and 
hypertrophy of the free wall of the left ventricle and inter-ventricular septum (IVS) are the 
characteristic feature of HCM. Figure modified from Chung et al., 2003.   
 
HCM is a disease of the myocardium and is characterized by an increase in cardiac mass 
typically represented by asymmetric hypertrophy of the left ventricle which involves the 
inter-ventricular septum, in the absence of any external causes such as hypertension or aortic 
valve stenosis. Fig. 1 shows a typical hypertrophied heart in comparison to a normal heart. 
Usually the left ventricular volume is reduced and systolic pressure gradients are common. It 
was not until 1990 when for the first time a point mutation of a sarcomeric protein was 
identified as the primary cause of HCM (Geisterfer-Lowrance et al.,1990). The increase in 
cardiac mass is an outcome of the increase in the size or volume of the cardiomyocytes, 
rather than an increase in their number (hyperplasia). The hypertrophy is accompanied by 
interstitial fibrosis, which is characterized by the presence of more fibroblasts and associated 
extracellular matrix. The presence of intertitial fibrosis increases cardiac stiffness and causes 
further changes in the heart’s anatomy. The other most remarkable and distinguishing feature 
of HCM is myocyte and myofibrillar disarray (Richardson et al., 1996). (Fig. 2). The disease 
Introduction 
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is characterized by various symptoms such as, angina pectoris, shortness of breath or 
dyspnea, arrythymias, unexplained syncopes and one of the features of the disease which 
cannot be defined as a symptom is unexplained sudden death. 
 
2.2 Pathological hallmark of HCM 
 
 
 
 
 
a
HCM Normal
C
 
 
Fig. 2. Structure of the normal (A) and hypertrophied (B) myocardium. Myocte disarray is 
characterized by myocytes arranged around areas of interstitial fibrosis (C) Figure of 
sections of Hypertrophic and normal hearts showing the disarray and normal arrangements 
of myocytes, respectively. Figure modified from (Chung et al., 2003) 
Histological examination of the myocardium is fundamental to the diagnosis of HCM. The 
chief pathological features of HCM are myocyte hypertrophy and disarray along with 
increase in interstitial collagen deposition (Elliot and McKenna, 2004). In myocyte disarray 
the orderly alignment and organization of the myocytes is disrupted and adjacent myocytes 
get obliquely or perpendicularly oriented to one another around areas rich in collagen. The 
nuclei of the myocytes become enlarged, show different shapes and sizes (pleomorphic) and 
become darkly stained (hyperchromatic). However, even though the different pathological 
arrangement of the myocytes in a hypertrophied heart has no prognostic implications (S.E. 
A B 
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Hughes, 2004), yet the development of myocyte disarray possibly causes ventricular 
arrhythmias. 
 
2.3 Genetics of Hypertrophic cardiomyopathy 
According to linkage analyses in different families, genes present on separate chromosomes 
are known to cause a disease with common phenotypic effects e.g., myocyte hypertrophy and 
disarray (Fokstuen et al., 2008). To date, at least 16 different genes have been identified 
(Table 1), mutations in which cause hypertrophic cardiomyopathy. Most of these disease 
causing genes encode proteins of the structural and functional unit of the muscle cell – the 
sarcomere. 
 
The allusion of HCM as a disease of the sarcomere is justified, as mutations in several 
sarcomeric proteins are known to be the chief cause of this disease. These proteins include 
myosin heavy chain (MHC), essential and regulatory light chains (ELC, RLC), cardiac 
troponin I (TNNI3), cardiac troponin T (TNNT2), cardiac myosin binding protein C 
(MYBPC3), "-tropomyosin (TPM1) and cardiac actin (ACTC). Mutations in several other 
non-sarcomeric proteins like Caveolin-3 (Hayashi et al., 2004) and the phospholamban 
promoter (Minamisawa et al., 2003) have also been implicated as causes of the disease, but 
these mutations are very rare in HCM so far.  
Introduction 
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Fig. 3. Schematic representation of a sarcomere. The myofibril shows the alternating light 
bands (I bands) composed of thin filaments and dark bands (A bands) composed of thin and 
thick filaments. The thin filament proteins include actin, tropomyosin and troponins C, T and 
I. The thick filament proteins include myosin heavy chain, myosin regulatory and essential 
light chains and myosin binding protein C. Titin serves as an anchor between the Z disk and 
the thick filaments. (Figure modified from Morita et al., 2005 and Redwood et al., 1999).  
Introduction 
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Gene Locus Protein Number of mutations 
MYH7 14q12 !-Myosin heavy chain 193 
MYBPC3 11p11 Cardiac myosin binding protein C 138 
TNNT2 1q32 Cardiac troponin T 33 
TNNI3 19q13 Cardiac troponin I 32 
CSRP3 11p15 Cardiac muscle Lim protein 12 
TPM1 15q22 "-tropomyosin 11 
MYL2 12q23 Regulatory myosin light chain 10 
ACTC 15q14 Cardiac actin 7 
MYL3 3p21 Essential myosin light chain 5 
PRKAG2 7q36 AMP-activated protein kinase 4 
PLN 6q22 Phospholamban 2 
TNNC1 3p21 Cardiac troponin C 1 
TTN 2q31 Titin 2 
MYH6 14q11 "-myosin heavy chain 2 
TCAP 17q12 Telethonin 2 
CAV3 3p25 Caveolin-3 1 
Total   455 
 
Table 1. HCM as a disease of the sarcomere. The above table illustrates the chromosomal 
loci and mutation frequency of the chief sarcomeric and non-sarcomeric proteins which are 
implicated in hypertrophic cardiomyopathy. The table is modified from Fokstuen et al., 2008.  
 
Out of the above-mentioned sarcomeric proteins, mutations in the !-myosin heavy chain are 
the most frequently occurring and account for about almost 40% of all HCM cases  (Fokstuen 
et al., 2008). The disease is transmitted chiefly as an autosomal dominant disorder, in which 
case it is familial. Most HCM patients are heterozygous for the causative mutation. The 
frequency in the general population is 1:500 (Maron et al., 1995). When the causal mutation 
occurs de novo in an individual neither of whose parents are clinically or genetically affected, 
the disease is said to be sporadic. It has, however been difficult to estimate the fraction of 
HCM that occurs sporadically. In two different studies it has been suggested that HCM was 
sporadic in 44% and 33%, respectively (Maron et al., 1984; Greaves et al, 1987).  
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2.3.1 Beta myosin heavy chain gene  
Myosin is the chief component of the muscle thick filaments. It has been shown that the 
MYH7 gene is 22,883 bp long (Jaenicke et al., 1990) and the locus for this gene is 14q13 
(Matsuoka et al., 1989). The gene comprises 40 exons, out of which the first two are non-
coding (Liew et al, 1990).  This gene encodes a 1935 amino acids long polypeptide. In 
humans the !-myosin is expressed in the ventricles and also in slow skeletal muscle fibers. 
 
2.3.2 Myosin structure and ventricular myosin mutations 
Myosin is an actin activated ATPase that converts the chemical energy of ATP into 
mechanical energy. Following the hydrolysis of ATP, the myosin heads can bind to actin 
with high affinity. Conformational changes of the myosin head upon Pi and ADP release will 
pull the actin towards the center of the sarcomere. Repeated cycling of the acto-myosin cross-
bridge will cause sliding of the actin filaments and muscle shortening.  
A myosin molecule comprises of six subdomains with a total molecular weight of 520 KDa. 
It consists of two globular heads formed by two heavy chains (each about 220 KDa) and four 
light chains, two ELCs and two RLCs, each of approximately 20 KDa. The myosin heavy 
chain has two major functional parts. The amino terminal globular domain to which the light 
chains bind, is the motor domain consisting of the ATP binding site and the actin binding 
site. The catalytic activity of the myosin molecule also resides in the head domain. The rod of 
the molecule comprising an alpha-helical coiled-coil elongated structure forms the backbone 
of the thick filaments. Myosin heads which can form physical links between the thick and the 
thin filaments are called cross bridges. 
The cycling crossbridge model links events of ATP hydrolysis with force generation.  
Between the cross bridge conformation at the beginning and end of the power stroke, the 
lever arm of the myosin molecule is thought to rotate approximately 60 to 70 degrees, 
causing the displacement of actin (Geeves et al., 1999). 
Most of the HCM causing !-myosin mutations are missense mutations causing a change of a 
single amino acid in the mutated molecule, and the patients are mostly heterozygotes. !-
myosin head domain mutations studied in our laboratory are examples of such mutations. Fig. 
4 shows the location of the mutations in the myosin head domain reported in this study  
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Fig. 4. Structure of a !-MHC head domain with the locations of the mutations under study.  
 
However, very few cases have also been reported where the affected patients have either the 
identical mutations on both !-MHC alleles (homozygotes) (Nishi et al., 1994) or different 
mutations on each allele (compound heterozygote) (Mohiddin et al., 2003). 
 
2.4 Putative HCM causing Mechanisms  
Different mechanisms of phenotype development in HCM have been postulated in the past. 
To date there is, however, no conclusive evidence for a common denominator or mechanism 
common to all HCM causing mutations which would trigger the development of HCM. In the 
following paragraphs examples will be given for different mechanisms how a mutation might 
initially affect myocardial function. 
 
2.4.1 Dominant-negative mechanism 
According to the dominant-negative mechanism, the mutant and the wild type alleles produce 
the mutant and wild type proteins, respectively. Both kinds of proteins are integrated into the 
sarcomere. The mutant protein has a new and/or enhanced and aberrant function. The 
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incorporation of the mutant (Mut) protein, which acts as a ‘poison polypeptide’, into the 
sarcomere affects the function of the wild type (WT) protein. 
 
 
 
Fig. 5. Dominant-negative mechanism of HCM. From the Mut (asterisk) and WT genes, Mut 
and WT mRNAs are transcribed which are translated into the corresponding proteins. The 
proteins are incorporated into the contractile apparatus where the aberrant Mut protein 
exerts its functional effects and causes myocyte hypertrophy and disarray. Figure taken from 
Seidman et al., 1998. 
 
Protein quantification done in our laboratory on different !-MHC missense mutations 
implicated in HCM, performed by chemical permeabilization of muscle fiber membranes to 
wash off any soluble and free myosin that has not been incorporated into the sarcomere, has 
demonstrated that mutated protein is present in the sarcomeres (Nier et al., 1999; Becker et 
al., 2007). Mechanical and X-ray diffraction experiments done by Köhler et al., 2002 have 
shown that integration of the mutated !-myosin into the sarcomeres does not cause alterations 
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in the structure and assembly of thick filaments. Therefore, the myosin heavy chain mutations 
cause their HCM effects due to a change in the functional properties of the myosin molecule.  
R403Q mutation in the actin-binding loop of the myosin heavy chain (Geisterfer-Lowrance et 
al., 1990) is one of the most lethal HCM-causing mutations and has been important in the 
studies trying to uncover the mechanisms underlying hypertrophic cardiomyopathy. It was 
shown by Tyska et al., 2000 that myosin isolated from mice hearts engineered to have the 
R403Q, exhibited a higher actin activated ATPase activity, greater generated force and 
accelerated actin filament sliding. Recently, Belus et al., 2008 have also shown that in single 
ventricular myofibrils carrying the R403Q mutation in the myosin heavy chain, tension 
generation and relaxation were much faster, compared to controls, when Ca++ was suddenly 
increased and decreased. Such gain in function, although it accounts for improved motor 
performance of R403Q molecules, yet the associated increased ATPase activity results in the 
increased energy consumption by the hypertrophic heart and might lead to cell death. Since 
the myocardium is a terminally differentiated tissue, the cells essentially do not replicate or 
regenerate and proliferation of cardiac fibroblast occurs. The occurrence of replacement 
fibrosis is a well-documented feature of HCM. 
However, in another study to investigate the functional effects of the HCM associated !-
myosin mutation R403Q, it was found that the mutant myosin had normal ATPase activity in 
the absence of actin. In the presence of actin, the mutant functioned like a poison polypeptide 
causing a decrease in the ATPase activity and the velocity of actin translocation in in vitro 
motility assays (Sweeney et al., 1994).  
This indicates that results for the R403Q mutation are not consistent in all studies and in all 
tissues. When HCM mutations are expressed in transgenic animals, they do not necessarily 
induce the same functional changes in the sarcomeres of these animals as in human 
myocardium. This has been shown in a study by Lowey and colleagues in 2008, where either 
the cardiac "- or the !-MHC isoforms were expressed in mice. It was demonstrated in in 
vitro motility assays that the actin filament velocity was enhanced by 30-40% in the R403Q 
"-MHC animals when compared with the wild type animals, whereas the mutation R403Q in 
the !-MHC backbone did not enhance the velocity of actin. It was also observed that the actin 
activated MgATPase activity of the R403Q-"-MHC was approximately 30% higher than the 
wild type, whereas, that for R403Q in the !-MHC backbone was reduced by approximately 
10%. Thus, the contradictory results in the literature for mutation R403Q may depend on the 
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source of the mutated myosin. These observations underline the importance of studying the 
effects of HCM mutations in the respective human protein isoform and if possible, in human 
tissue. 
 
2.4.2 Loss-of-function mutations 
Normally the wild type allele of a given gene codes for a protein that is necessary for a 
specific biological function. When a mutation occurs in this allele, the function associated 
with its protein product may be lost. The mutation, in this case, is referred to as a loss-of-
function mutation. The extent to which the function of the protein is lost varies. When there 
is a complete loss of function, then the mutation is referred to as a null mutation. Loss-of-
function mutations confer a recessive phenotype to the organism. Usually the protein encoded 
by the wild type allele is sufficient to compensate for the loss of function in the protein due to 
the mutated allele. In this case the wild type allele is said to be dominant and the mutated 
allele is referred to as recessive.  
Missense mutations in the !-MHC have been reported to cause a loss-of-function. The 
mutation G741R, located in a mutational hot-spot area of the !-MHC (Bonne et al., 1998), 
decreased the maximum velocity of shortening (39% of normal) and caused reduced 
isometric force generation (42% of normal) (Lankford et al., 1995). This mutation seems to 
cause a decreased power output and therefore, the hypothesis was developed that to ensure 
normal mechanical performance of the heart, compensatory hypertrophy might follow.  
 
2.4.3 Haploinsufficiency  
Haploinsufficiency is described as a condition in diploid organisms when one allele of a 
given gene is inactivated through a dominant mutation producing amounts of protein from the 
wild type allele that is ‘insufficient’ for normal function. This mechanism involves a 
quantitative rather than a qualitative change in the polypeptide and therefore leads to 
impaired myocyte mechanical function (Marian et al., 2001; Dalloz et al., 2001). Some 
deletion mutations can lead to a ‘null allele’ in which the spurious gene product is absent and 
only 50% of the total protein is normal and responsible for executing its given function. Since 
the proper functioning of muscle cell depends on the structural and functional integrity of the 
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sarcomere, it is important that each component of the contractile apparatus be present in 
appropriate stoichiometry.  
Most HCM causing cardiac Myosin Binding Protein C (cMyBPC) and cardiac Troponin T 
(cTnT) mutations are defects in splice signals which encode either truncated or aberrant 
polypeptides (Bonne et al., 1995; Rottbauer et al., 1997; Thierfelder et al., 1994) In a mouse 
model of cTnT null allele, cTNNT (-/-), the thick and thin filaments and alpha actinin 
positive Z disk like structures were not  assembled into the sarcomere leading to embryonic 
lethality. On the other hand, the cTnT(+/-) mice had a normal life span (Nishii et al., 2008). 
Thus for survival, at least one normal allele of a sarcomeric gene is necessary. 
Yet, most likely haploinsufficiency is not a common mechanism in HCM. Quite a few studies 
have shown that the mutated alpha fast tropomyosin (Bottinelli et al., 1998) and mutated !-
MHC ( Köhler et al., 2002; Kirschner et al., 2005; Becker et al., 1997; Cuda et al., 1993; 
Palmiter et al., 2000; Malinchik et al., 1997; Nier et al., 1999; Becker et al, 2007, ) peptides, 
instead of being degraded, are incorporated into the sarcomere. Thus, the stoichiometry of the 
sarcomeric components is maintained through the expression of both the mutated and wild 
type sarcomeric proteins. 
 
 
2.5 Animal models of HCM 
Since human muscle tissue is a limiting factor in the study of the disease and is usually 
obtained post mortem or during heart transplantation operations, animal models of HCM with 
human mutations engineered into genes of sarcomeric components provide an important tool 
to study the functional impacts of such mutations on disease etiology. So far, mutations of the 
myosin heavy chain, cardiac MYBPC and TNNT that cause HCM in humans have been 
engineered into the genomes of animals.  
 
2.5.1 Mouse models 
In mice, at the embryonic and fetal stages !-MHC is the predominant isoform, whereas, soon 
after birth the "-MHC expression is up-regulated and becomes the chief myosin isoform in 
the ventricles (Weiss et al., 1996). The first reported !-MHC mutation, R403Q, was 
introduced into the mouse genome at the "-MHC locus by targeted homologous 
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recombination (Geisterfer-Lowrance et al., 1996). Therefore, in an "-MHC+/403 mouse a 
glutamine codon is present at the nucleotide position corresponding to the 403 amino acid 
position in the "-MHC polypeptide, instead of the normal arginine codon in one allele. The 
other allele is wild type and hence expresses the polypeptide with the arginine residue. The 
R403Q mutation in the !-MHC of humans presents a very severe form of HCM in which 
approximately 50% of the affected individuals die even before they are 45 years old. 
Seemingly consistent with this finding, Geisterfer-Lowrance and colleagues have shown that 
one out of five "-MHC+/403 mice died suddenly when subjected to vigorous physical activity 
like swimming. The dead mouse had an enlarged heart and marked left ventricular 
hypertrophy (Arad et al., 2002). On the contrary, these mice show no overt symptoms and 
have a normal life span when they are physically inactive.  
Murine models provide important information as regards the mechanism by which mutated 
sarcomeric proteins cause HCM. These models confirm the notion that the mutated proteins 
are synthesized and are stably incorporated into the contractile apparatus of the mice.  
Although the transgenic murine models elucidate the basic principles of HCM, yet they suffer 
from certain drawbacks.  There exists a significant difference in the sarcomeric protein 
isoform composition of humans and mice. In humans, the !-MHC is the chief adult 
ventricular myosin isoform, whereas, "-MHC is the principal ventricular myosin isoform in 
adult mice. Therefore the exact progression of HCM in mice due to mutations in the !-MHC, 
other than R403Q, and the corresponding phenotype is a matter of speculation due to the 
differences in amount of myosin isoforms in the human and murine hearts. 
 
2.5.2 Rabbit models 
In adult rabbits !-MHC comprises about 80% of the total endogenous myosin similar to 
humans where !-MHC is the predominant isoform comprising >90% of total ventricular 
myosin (Swynghedauw B, 1986).  One major advantage of rabbit models over mouse models 
is that the human and rabbit !-MHC proteins are approximately 98% homologous (Jaenicke 
et al., 1990; Kavinsky et al., 1984). A transgenic rabbit was created by injecting into 
fertilized rabbit zygotes, the transgene formed by cloning the mutant and wild type human !-
MHC cDNAs, with or without the R403Q mutation, downstream of murine !-MHC promoter 
(Marian et al., 1999). In these animals also the expression of the mutated transgene mRNA 
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and protein was demonstrated. The animals with the mutated transgene showed marked 
myocyte disarray and an increased interstitial collagen in the myocardium. The septum-
thickness was significantly increased in animals expressing the mutated transgene compared 
to wild type transgenic animals. It was also found in this study that in mutant transgenic 
rabbits, premature death was more common. 
Another study on transgenic rabbits with the R403Q mutation in the !-MHC gene has been 
reported (Nagueh et al., 2004) which tries to elucidate the human HCM by tracing the chain 
of evolutionary events that lead to the develoment of the cardiac phenotype. It was observed 
that the Ca++ sensitivity of the myosin ATPase activity was decreased in the absence of other 
phenotypes. Myocyte disarray in the rabbits carrying the mutated transgene occurred quite 
early and was independent of hypertrophy and interstitial fibrosis, which occurred during 
puberty as a result of activation of stress-related signaling pathways.  
It should however, be noted that also the rabbit model has its drawbacks. It is not clear 
whether the observed effects are solely caused by the mutation. The effects could also be 
partially due to the fact that in these animals, human wild type and mutant !-myosin is 
expressed together with endogenous rabbit !-myosin resulting in a mixture of different 
myosin isoforms present. 
 
2.5.3 Limitations of animal models 
Although the animal models recapitulate various features of HCM, there are differences 
between these models and human disease. The use of murine models is complicated by the 
fact that the different ventricular MHC isoforms are expressed in the mouse ( "-MHC) and 
human (!-MHC) myocardium. Also, the experimental animal models produced by transgenic 
approaches may result in higher levels of mutant protein encoded by the transgene than 
would be produced endogenously by a single mutated allele for a dominant human disorder. 
Hence, the effects of the transgene may be exaggerated. Moreover, inherent 
electrophysiological differences in the cardiac function, e.g. heart rate, between mice and 
humans has been recognized; the heart rate is ten-fold lower in humans than in mice (London 
B, 2001). Furthermore, the effects of exercise on these animals may be underestimated in a 
laboratory environment. Therefore, the utility of murine models as an accurate predictor 
cardiac arrhythmias and sudden death remains a point of debate. 
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This further emphasizes that studies on human tissues are important where the genes 
encoding the mutated protein are present in their natural milieu and thus the effects of 
extraneous factors on HCM expression and progression can be negated.  
 
2.6 Genotype-phenotype correlations 
HCM in humans is a genetically heterogenous disease caused by mutations in various 
sarcomeric proteins. Mutations in different proteins seem to lead to a different clinical 
outcome. For example, it is now known that mutations in cardiac TNNT are associated with 
mild hypertrophy, but high incidence of sudden death, which sometimes occurs even without 
a pronounced left ventricular hypertrophy (Moolman et al., 1997). Mutations in the cardiac 
MYBPC are associated with mild phenotype, delayed age at the onset of symptoms and a 
favorable prognosis before the age of 40 (Niimura et al., 1998; Charron et al., 1998). 
However for mutations in the !-MHC, the expression of the phenotype varies considerably 
with different mutations as well as with the identical mutation. Hence, the prognosis for 
various patients differs. Several mechanisms could account for the large variability in the 
phenotypic expression of the disease. For example, the type of mutation and the functional 
alterations or impairment it causes in the sarcomere, which would also depend on the location 
of the mutation within the protein that carries it. The effect of postulated modifier genes also 
accounts for the phenotypic heterogeneity of HCM. Moreover environmental factors and the 
lifestyle of an individual are also factors that contribute toward the phenotypic variation of 
disease manifestation (Marian AJ, 2002).  
Some HCM causing missense mutations in the !-MHC protein, which alter the charge of an 
amino acid, have been found to be associated with a shorter life expectancy. Examples of 
such mutations are R403Q and R453C (Marian et al, 1998). These mutations are associated 
with increased risk of sudden death. Another mutation associated with a high risk of 
premature death is R719W. This mutation also produces a charge change, in the mutated 
protein, of -1 (Anan et al., 1994).  
The mutations F513C, V606M (located in the motor domain) and L908V (located in the 
head/rod junction) have been described as benign mutations (Anan et al., 1994). Each of 
these mutations is a conservative mutation because there is no change of charge associated 
with the mutated protein. The lack of change of charge may partly account for the favorable 
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prognosis associated with these mutations. Yet for mutation V606M there are contradictory 
reports that associate the mutation also with poor prognosis and the risk of sudden death 
(Havndrup. et al., 2001, Fananapazir et al., 1994). This example shows that the severity of the 
clinical outcome of an HCM causing mutation apparently depends not only on the net change 
of charge in the !-MHC due to the amino acid exchange. Attempts to establish a genotype-
phenotype correlation for myosin heavy chain mutations based on the net charge change have 
failed. In addition, despite a very large number of known myosin mutations to date no clear 
correlation of the phenotype with e.g. location of the mutation within the head domain or any 
other typical feature of the mutations has been found. 
 
2.7 Aims and Objectives of the current work 
From the work in our group we have evidence that besides the type and location of a 
mutation in the myosin molecule there might be another factor that could contribute to the 
variability in phenotype and particularly in severity of the disease. We previously observed a 
lack of functional effects of some !-myosin mutations in studies on single slow human 
muscle fibers from HCM patients (unpublished data). Based on this we determined the 
proportion of mutated !-myosin, which was incorporated into the sarcomeres of these muscle 
biopsies. The result was quite surprising because we found that in a patient with mutation 
V606M, only 12% of total myosin carried the mutation (Nier et al., 1999). In a patient with 
mutation G584R only 23±1% was mutated myosin in the contractile apparatus (Nier et al., 
1999). These findings were quite unexpected because HCM is inherited in an autosomal 
dominant fashion and thus approximately 50% mutated and 50% wild type myosin would be 
expected in the muscle tissue of the patients.  
Since a deviation from a 50:50 ratio in the expression of wild type and mutated protein 
occurred at the protein level, we asked whether the deviation was already present at the 
mRNA level. First experiments on two mutations (V606M and R719W) in skeletal muscle 
biopsies of HCM patients, which were carried out by I. Schulte in a previous dissertation 
(Schulte, 2001) showed that the fraction of mutated !-MHC-mRNA for mutation V606M 
was similarly low as found at the protein level. However, for mutation R719W, it was close 
to 50% at the protein and !-MHC-mRNA level. Therefore several open questions remained, 
which were addressed in the current work. 
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• It was not clear from the previous work whether the deviation from a 50:50 ratio 
observed for mutation V606M could also have been caused by formation of 
heteroduplexes between wildtype and mutant DNA strands. Such heteroduplexes are 
formed in a multi-template reaction at high cycle numbers during PCR, under limiting 
primer concentrations, when the denaturation/reannealing steps cause such 
heterologous sequences to hybridize (c.f. Fig 8). Formation of heteroduplexes would 
cause errors in the restriction digest used for relative quantification of the mutated and 
wild type !-MHC-mRNA. Therefore, one important part of the present work was to 
extend and modify the previously used method for the quantification of the fraction of 
mutated !-MHC-mRNA in muscle tissue of HCM patients. A control for 
heteroduplex formation which would affect the quantification had to be established 
together with generation of defined mixtures of mutant and wild type cDNA cloned 
into plasmids to test the method. 
• Since previously only for one mutation (V606M) a clear deviation from the 50:50 
ratio was found, in the current work we had to find out whether the deviation in the 
expression of wild type and mutated !-MHC-mRNA from 50:50 in soleus muscle 
also exists for other HCM causing mutations. 
• Another important question regarding the underlying mechanism of the deviation 
from a 50:50 ratio in the wild type and mutant !-MHC-mRNA was, whether the 
deviation is similar for a given mutation in several patients. We had muscle tissue 
available from five patients with mutation R723G and from three patients with 
mutation I736T so that we could address this question. In addition, since not all 
patients with the same mutation were siblings, we could also investigate whether the 
fraction of mutated !-MHC-mRNA in the muscle tissue exhibits an intra- and inter-
familial similarity. 
• Quite important with respect to the relevance of our results from soleus muscle 
biopsies of HCM patients for the myocardial disease in these patients was the 
question, whether the fraction of mutated !-MHC-mRNA is similar in the 
myocardium for a given patient and/or mutation. Although myocardial biopsies are 
very difficult to obtain, we were able to address this question with the myocardial 
tissue from two HCM patients with mutation R723G. 
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• Finally to further investigate possible reasons for the observed deviation from a 50:50 
ratio also in myocardium we set out to determine relative !-MHC-mRNA levels also 
in single cardiomyocytes. To achieve this goal in the future, a more sensitive method 
for the relative quantification had to be introduced to be able to perform relative 
quantification even on much smaller tissue samples like needle biopsies or even 
single myocytes obtained by the laser capture microdissection method. 
 
2.8 Methods used to address the question 
The above questions were mainly addressed with the newly established reconditioning PCR 
method for relative quantification of !-MHC-mRNA in muscle tissue. This method is based 
on reverse-transcription polymerase chain reaction (RT-PCR) followed by PCR and a 
reconditioning PCR step to ensure that no heteroduplexes are formed which would affect the 
subsequent enzymatic cleavage of the PCR products and falsify quantification of restriction 
fragments by densitometry.  
Yet, since the restriction digestion method requires large amounts of tissue, it is at its limit 
for single fibers and it cannot be used for single cell quantification, which is one of our future 
aims. Therefore we established a pyrosequencing method for relative !-MHC-mRNA 
quantification. 
 
Pyrosequencing 
In order to study the !-MHC-mRNA expression possibly at the single cardiomyocyte level 
we have started establishing a pyrosequencing method for relative mRNA quantification. In 
the work presented here, the method was used on larger biopsies. In principle, the method is 
based on sequencing PCR amplified DNA molecules (Diggle et al., 2004). 
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Fig. 6.  Schematic representation of the principle of pyrosequencing. The light produced in 
the luciferase catalyzed reaction is detected by a CCD camera and is seen as a peak in the 
pyrogram. 
 
In the first step of the reaction (Fig. 6), the PCR amplified single stranded PCR product is 
hybridized to a sequencing primer along with the enzymes DNA polymerase, ATP 
sulfurylase, luciferase and apyrase and substrates adenosine 5’ phosphosulfate (APS) and 
luciferin. 
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The dNTPs are added in a stepwise manner and if a complementary base is found in the 
template strand, the nucleotide is incorporated into the growing strand accompanied with the 
release of the pyrophosphate (PPi) in an amount equimolar to the incorporated nucleotide. 
The released PPi is quantitatively converted into ATP by the enzyme sufurylase in the 
presence of substrate APS. The ATP that is generated drives the conversion of luciferin into 
oxyluciferin in the presence of the enzyme luciferase and produces visible light that is 
proportional to the amount of ATP that was generated. The emitted light is detected by a 
charge coupled device (CCD) camera and is seen as a peak in the pyrogram. Since the light 
emitted at a specific step of the sequencing procedure is proportional to the the amount of PPi 
released and hence, to the amount of the respective dNTP incorporated into the growing 
DNA strand at this step, this method can be used for quantification of the fractions of mutated 
and wild type alleles in a sample. 
Apyrase enzyme continuously degrades the unincorporated dNTPs. The addition of dNTPs is 
performed one at a time. Deoxyadenosine alpha thio-triphosphate (dATPaS) is used as a 
substitute for the natural deoxyadenosine triphosphate (dATP). dATPaS is efficiently 
recognized by the DNA polymerase, but not by luciferase. 
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3 Materials and Methods 
 
3.1 Patients and muscle biopsies. 
The present study was performed on muscle biopsies from individuals who were previously 
clinically and genetically characterized as HCM patients with point mutations in the !-
myosin head domain. All of these patients were heterozygous for the mutations they carried. 
Soleus biopsies with the R723G mutation in the !-MHC head domain were obtained from 
two brothers H27 (57 years) and H28 (50 years) and another younger patient H71 (34 years) 
of a Catalan family (Enjuto et al., 2000). For H27, after heart transplantation, myocardium 
from anterior wall of the left ventricle was also available. Left ventricular myocardium from 
a female patient (H29, 53 years) of another family, with mutation R723G, was also obtained. 
From a third family, soleus muscle was available from another young patient, H72 (30 years). 
All the above-mentioned five patients carried R723G mutation in the !-MHC head domain 
(Enjuto et al., 2000). 
Another patient (H13), 22 years old at the time of biopsy, was a female from a British family 
and was characterized to be carrying !-MHC mutation Arg719Trp (Anan et al., 1994). She 
had moderate left ventricular hypertrophy (22mm) with reduced exercise capacity and 
received an ICD after cardiac arrest and resuscitation (NYHA Class I).  Another patient (H5), 
30 years old and nearly asymptomatic, was from a British family and carried the mutation 
V606M. The other three patients (H17, H18 and H19) were of a Krygyz family (Caucasian 
origin): two males and one female, and they all carried mutation Ile736Thr (Perrot et al., 
2005). They were 52, 55 and 50 years old, respectively, at the time of biopsy. Furthermore, 
they all were in functional NYHA class II with insignificant to moderate septal hypertrophy 
(14 mm, 18mm, 17mm, respectively). In addition, biopsies of the M. soleus of healthy control 
individuals, H24, H25 and H26, i.e., volunteers without any known impairment of cardiac 
function were obtained.  
The M. soleus biopsies of HCM patients and control individuals were excised under local 
anesthesia. All biopsies were approximately 10 X 10 X 15 mm. Immediately after surgery the 
biopsies were cooled and small muscle pieces were instantaneously shock-frozen in liquid 
nitrogen. Informed consent was obtained according to approved Ethics Committee protocols 
of all involved centers. The investigations conformed with the principles outlined in the 
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Declaration of Helsinki (World Medical Association, 1997). Due care was taken that this 
procedure occurred very fast and with immediate cooling of the muscle tissue. The entire 
procedure of sample preparation was the same for all biopsies taken and was carried out by 
the same people at the respective hospitals in Barcelona, London or Hannover (for the 
Kyrgyz patients). Only for the mRNA analysis of muscle tissue with mutation V606M, tissue 
was used that had originally been prepared at the time of biopsy for cryo-sectioning and 
histological examination. Prior to shock-freezing in liquid nitrogen this muscle biopsy was 
mounted on cork using tissue freezing medium. The biopsy was stored at –80°C at all times 
except for cryo-sectioning, so that intact mRNA could be obtained. All the other biopsies 
were stored in liquid nitrogen until mRNA-isolation. 
 
3.2 RNA isolation, synthesis of sscDNA and PCR 
Total RNA was isolated from around 3mg of frozen samples from M. soleus biopsies of the 
different patients with mutations R719W and I736T, including the biopsy with mutation 
V606M, using Trizol (GIBCO BRL Life Technologies, Karlsruhe, Germany). Isolated RNA 
was reverse-transcribed into cDNA (SuperScript First-Strand Synthesis System for RT-PCR, 
GIBCO BRL Life Technologies, Karlsruhe, Germany). For mutation R723G the RNA 
isolation, from both myocardium and soleus muscle, and cDNA synthesis steps were 
performed using  a cells-to-cDNA kit (Ambion) according to the manufacturer’s 
recommendations. For reverse-transcription (Fig. 7A and 7B) a common gene specific primer 
RTR719W (Table 2) was used for all mutations. The primer was placed over an intron22-
exon23 junction (all nucleotides are numbered according to the GenBank accession number 
X52889) to reverse transcribe only mRNA and to increase the specificity of the product. 
Primers were designed to specifically amplify regions of cDNA encompassing the mutation 
site. A summary of all the primers is found in Table 2. All PCR was carried out in a final 
volume of 50"l. The PCR conditions using a thermocycler (Mastercycler gradient, 
Eppendorf, Hamburg, Germany) were the same for mutations R719W, I736T and V606M. It 
comprised 1 minute of initial denaturation at 94°C, 22-28 cycles of 30 seconds of 
denaturation at 94°C and 3 minutes of annealing and primer extension at 68°C, final 
elongation for 3 minutes at 68°C. To obtain highly specific PCR products and prevent 
background due to DNA synthesis from nonspecifically primed sites, the polymerase mix 
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contained a proofreading enzyme and polymerase antibodies. For mutation R723G, the 
thermal-cycling included a step of enzyme activation at 95°C for 15 minutes as recommended 
by the manufacturer. The other steps included denaturation at 95°C for 1 minute, primer 
annealing at 68°C for 30 seconds and an extension at 72°C for 2.5 minutes. The 
denaturation/annealing/extension cycle was repeated for 35 cycles. A final extension at 72°C 
was done for 5 minutes. 
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Fig. 7A. Synthesis of cDNA from mRNA using a gene specific primer (GSP). Using a GSP, 
instead of random hexamers or oligo-dTs ensures the generation of specific cDNAs from the 
mRNA; RTase, reverse transcriptase. 
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Fig. 7B. An example of the reverse transcription polymerase chain reaction (RT-PCR) 
performed on ventricular biopsy of patient H27. Lane 1, Low DNA Mass Ladder; Lane 2, 
Blank for PCR in which nuclease free water was used as template instead of the cDNA; Lane 
3, Blank at the reverse transcription level wherein nuclease free water was used as template 
instead of mRNA; Lane 4, Blank for RT step wherein lysis buffer was used as template 
instead of water or mRNA; Lane 5, -RT reaction where the template mRNA was used for RT 
without the addition of the reverse transcriptase enzyme to the reaction; Lane 6, +RT 
reaction where the template mRNA was reverse transcribed into cDNA  which was 
subsequently used for PCR. Each lane was overloaded in order to facilitate the detection of 
even the slightest trace of contamination. 
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 Primer name Primer sequence 5’-3’ 
!-MHC gene specific 
reverse transcription 
primer 
 
RTR719W 
 
TGC CAG GTT GTC TTG TTC CG 
 
Myosin mutations   
 
   
FEx16 606 
Forward 
 
 
TCC CCA AGG CCA CCG ACA TGA CCT TCA AGG CCA AGC 
TGT TT 
 
 
 
 
V606M 
 
RExon 16 II 
Reverse 
 
 
CTT TGC CCT TCT CAA TAG GCG CAT CAG 
 
 
719F 
Forward 
 
 
ACG AAG TCT CCA GGC GTG ATG GAC AAC C 
 
 
 
 
R719W 
 
719R 
Reverse 
 
 
CTT TTT GTA CTC CAT TCT GGC GAG CAC A 
 
 
736F’ 
Forward 
 
 
ACA AAG TCT CCA GGC GTG ATG GTC AAC C 
 
 
 
 
I736T 
 
719R 
Reverse 
 
 
CTT TTT GTA CTC CAT TCT GGC GAG CAC A 
 
 
R723G Mut F 
Forward 
 
CCA ACC GCA TCC TCT ACG GGG ACT TCC GGC AGA GGG 
AT 
 
 
 
 
R723G 
 
719R 
Reverse 
 
 
CTT TTT GTA CTC CAT TCT GGC GAG CAC A 
 
 
Table 2. Summary of primer sequences. The bold (T) in 736F’ forward and the bold (G) in 
R723G Mut F primers are the base changes introduced into the !-MHC sequence for the 
respective mutations. 
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3.3 Restriction Digests  
The PCR products were digested with the following restriction enzymes, according to the 
manufacturers’ recommendations, for discriminating between the wild type and the mutated 
fragments: NdeII for R723G, MspI for R719W, Hpy8I for I736T and NlaIII for V606M. In 
order to distinguish the uncleaved PCR product from the wild type PCR product e.g., for 
mutation I736T (cf Fig. 11A), the PCR products were completely digested for all mutations. 
Primers and enzymes were chosen such that all PCR products contained at least one cleavage 
site for the respective enzyme. Conditions of digestion were optimized to ensure complete 
digestion in all cases.  
 
3.4 Reconditioning PCR to avoid heteroduplex formation 
A relatively high cycle number (35 cycles) was used to obtain the PCR product. To avoid the 
formation of heteroduplexes between wild type and mutant strands in the final PCR product, 
which was used for restriction digest and relative quantification, a reconditioning PCR 
method was used (Thompson et al., 2002; Becker-Andre et al., 1989). To achieve this, the 
PCR product of 35 cycles was diluted 1:5 in nuclease free water (Ambion) and 2.5"l were 
used in a 50"L reaction so that the final dilution was 1:100. To ensure that the cDNA used 
for quantification was obtained from a linear range of PCR, several such reaction mixtures 
were prepared. Each of these reactions were run for different cycle numbers (McCarrey et al., 
1992) so that a PCR curve could be generated to determine the exponential range of the 
reaction (Fig. 8B, an example for mutation R723G, patient H28 is shown). For the example 
shown in Fig. 8B, this would be from the 1st until the 7th cycle. For quantification, the 
samples were taken from the exponential range of the reaction only. About 10 aliquots of 
PCR product from a particular cycle in the exponential range were pooled. The pooled PCR 
product was precipitated overnight with 3M sodium acetate (final concentration 200 mM) 
and 3 volumes of absolute alcohol at -80°C.  
 
Cloning the 125bp fragment for estimation of heteroduplex formation 
From the mutant PCR product (of 35 cycles) of patients with mutation R723G, the 125bp 
fragment (Fig. 8A) was excised from the agarose gel. The DNA in the gel piece with this 
fragment was purified using Gel purification kits (Qiagen). The isol
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cloned into pAlli10 vector using the Alligator Cloning Kit (Trenzyme Biotechnology). 
Cloning of this fragment was carried out to estimate the possible formation of heteroduplexes 
in a PCR where the product is obtained at high cycle numbers. The clones were sequenced at 
GATC (Konstanz, Germany) in the forward as well as reverse orientations.  
 
3.5 Relative quantification 
The DNA-fragments generated by the restriction digests were separated on 2,5% or 3,5% 
ethidium bromide (EtBr) agarose gels, using an agarose specific for high resolution of DNA 
bands (Metaphor or NuSieve agarose, FMC Bioproducts, Rockland, USA). For relative 
quantification of the different bands it was necessary to ensure that the intensities of the 
relevant bands were all in the linear intensity range of the gel and that the intensities 
corresponded to the amount of DNA in the respective bands. Therefore, different volumes of 
an equimolar DNA-standard (Low DNA Mass Ladder, Invitrogen AG, Basel, Switzerland) 
were run on each gel parallel to the restriction digests (Fig. 8C). This ladder consists of six 
DNA fragments. The lengths of the three faster-migrating fragments (400bp, 200bp and 
100bp) relevant for our method are in the ratio 4:2:1. Since the ladder is equimolar, the 
fragments are present in equal numbers, i.e. the amount of DNA contained in the equimolar 
standard for each of these fragments is also in a 4:2:1 ratio (known from the company). 
Hence, if 1"l of DNA-standard is run on the gel, the amount of EtBr incorporated into each 
of these three fragments corresponds to their respective lengths i.e., also in the ratio 4:2:1. If 
IODs of the bands from lanes with different volumes of the DNA standard are plotted vs. the 
amount of DNA in each band, a linear relationship is expected. In an equimolar standard the 
bands in one lane should all have the same IOD/bp ratio or the same relative amount so that 
the ratio IOD/bp for the three bands of 400bp, 200bp and 100bp should appear in a 1:1:1 
relation. 
Intensity profiles of the individual bands of the equimolar DNA-standards and of the 
restriction digests of patient cDNA on the gels were obtained densitometrically using the Gel-
Pro Analyzer software (Media Cybernetics, Maryland, USA and Total Lab Software 
(Biostep). The intensities of the peaks from the individual bands were obtained by curve 
fitting using the software Origin# (Microcal# Software, Northampton, MA, USA).  
The bands of at least three lanes of standard on each gel were analyzed to check for linearity 
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of the plot and to ensure that intensity saturation had not been reached.  
A measure for the amount of DNA in each band of the restriction digests was obtained by 
calculating the ratio of the total integrated intensity of this band over length of the respective 
fragment (IOD/bp). The fraction of mutated mRNA in each restriction digest was calculated 
from the IOD/bp ratio of a fragment exclusively from the mutant (e.g., the 125bp fragment in 
Fig. 8A) vs. the IOD/bp ratio of a fragment exclusively from the wild type (e.g. the 90bp 
fragment in Fig. 8A) or vs. the average of the IOD/bp values of two wild type fragments 
(mutation R719W). This ratio was taken as a measure for the fraction of mutated !-MHC 
mRNA isolated from the myocardium and/or soleus muscle samples of each patient. In some 
cases the ratio of the IOD/bp values of two fragments cleaved from the mutant or from the 
wild type, respectively, was calculated as internal control (e.g., the ratio of the 149bp and the 
205bp fragments of mutation I736T). 
 
Control experiments to test the relative quantifications with known plasmid mixtures 
281bp wild type and mutated MYH7 sequences, encompassing the site of mutation R723G 
and thus, differing only by a single nucleotide (c/g), were cloned into plasmid pGA4 between 
the restriction sites KpnI and SacI (Geneart, Regensburg, Germany). We generated several 
defined mixtures of these constructs containing either wild type or the mutant sequences. The 
mutant:wild type ratios in these mixtures were 20:80, 40:60, 50:50, 70:30, 90:10. 
Amplification occurred with the primers for R723G (Table 2). For the plasmid mixtures we 
generated a PCR curve, like for patient cDNA (Fig 8B), to ascertain the PCR cycle number at 
which the reaction was still exponential. Since our objective was to determine whether the 
input ratios of mutant:wild type would be the same as the output ratios, reconditioning PCR 
was not done on plasmid mixtures. The restriction digestion, gel analysis and quantification 
of the fraction of mutated vs. wild type plasmid in the mixtures were done as described 
earlier for the DNA standard and patient samples. 
 
3.6 Single fiber analysis 
Single fibers were isolated from a freeze-dried soleus muscle biopsy of patient H27 with 
mutation R723G for relative !-MHC-mRNA quantification. Presence of water in the tissue is 
detrimental to biomolecules because it facilitates enzymatic hydrolysis or chemical oxidation. 
Freeze-drying was advantageous in the extraction of single fibers from the muscle piece 
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because the removal of water rendered the muscle piece quite brittle. Isolation was done in 
small plastic chambers surrounded by silica gel to keep the muscle sample dry. The 
procedure of cDNA preparation, PCR (for single fibers reconditioning PCR was not used) 
and relative quantification was the same as described for larger biopsy pieces. 
 
3.7 Pyrosequencing 
Pyrosequencing experiments were carried out at the Institute for Pathology in collaboration 
with Prof. Dr. Ulrich Lehmann. First we optimized and tested the pyrosequencing method to 
ensure that it can be used for the relative quantification of !-MHC-mRNA. We prepared 
plasmids with genomic DNA and cDNA, respectively, which carried the R723G mutation. 
Subsequently, control experiments were carried out also on cDNA prepared from tissue of 
healthy controls and HCM patients.  
 
Plasmids carrying genomic DNA inserts 
Wild type and mutant genomic DNA inserts of size 275bp from the MYH7 sequence (intron 
19, position 12111- exon 20, position 12385) containing the site of the R723G mutation were 
cloned into pGA4 vector between KpnI and SacI restriction enzyme sites (Geneart, 
Regensburg, Germany). 
 
Plasmids carrying cDNA inserts 
MYH7 cDNA inserts, 281bp in size, encompassing the site of mutation R723G were cloned 
into plasmid pGA4 between the restriction sites KpnI and SacI (Geneart, Regensburg, 
Germany).  
 
The wild type and mutant genomic DNA plasmids and wild type and mutant cDNA plasmids 
were mixed in specific ratios. The ratios of the wild type vs. mutant plasmids in these 
mixtures was 100:0, 90:10, 75:25, 50:50, 25:75, 10:90 and 0:100, respectively. PCR was 
performed on these mixtures using the primers listed in Table 3.  
 
Pyro-PCR 
The genomic DNA or cDNA sequences in the plasmid mixtures were amplified. The 
amplification conditions included an initial denaturation step of 95oC for 1 minute, primer 
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annealing at 60oC and extension at 72oC for 2.5 minutes. The denaturation-annealing-
extension cycle was repeated 45 times. The primers used for the pyro-PCR are listed in Table 
3. The reverse primer has a biotinylated tail. Therefore, the PCR product that is obtained is 
biotinylated. This is important for a subsequent step where the biotinylated PCR product is 
bound to streptavidin sepharose beads. These beads are then vacuum sucked onto a hand-grip 
and released into a denaturing solution, where the hydrogen bonds between the two strand of 
the DNA double helix are broken. 
As a next step, pyro-PCR was also performed on cDNA from patients and controls. Yet the 
conditions for this non-circular cDNA of tissue origin has not yet been fully optimized.  
 
Template Primer 
sense 
Primer name Primer sequence 
Forward cBMH-F1 5’-CCC CAA CCG CAT CCT CTA-3’ cDNA 
Reverse cBMH-R1-tail 5’-(GGG ACA CCG CTG ATC GTT TA) G 
GAT GGC CGC TGG GT-3’ 
Forward BMH-F2 5’-CAG ACT CAC TGC AGA GCA TGG-3’ Genomic 
DNA Reverse cBMH-R1-tail 5’-(GGG ACA CCG CTG ATC GTT TA) G 
GAT GGC CGC TGG GT-3’ 
 
Table 3. List of primers used for pyro-PCR. 
 
 
 
Template Sequencing 
primer 
Primer sequence 
cDNA cBMH-pyro 5’-TTC CGG CAG AGG TA-3’ 
Genomic DNA BMH-pyro 5’- CTT CCC TCC TCA GGT A-3’ 
 
Table 4. list of sequencing primers used for pyrosequencing. 
 
 
Statistics 
Results are presented as the mean±SD of at least 7 or more restriction digests from at least 2 
or more pieces of the muscle biopsies of each patient. Stastical comparison between two 
experimental groups were performed using Student’s 2-tailed t-test (p values #0.05 were 
considered significant).  
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4 Results 
 
4.1 Relative quantification of mutant fragment in defined mixtures of 
plasmids. 
To test our experimental method and detection system, we investigated whether in artificially 
generated heterozygous samples the input fraction of a specific allele would be equal to the 
output fraction after PCR. We used plasmids, which carried as inserts a MYH7 sequence 
containing the site of the R723G mutation, which upon amplification with the R723G primers 
yielded a 281bp PCR product. These plasmids carried either the wild type or the mutant 
inserts differing only by a single nucleotide (c/g). Known mixtures of these plasmids were 
generated in which the mutant and wild type sequences were present in the ratios 0:100, 
20:80, 40:60, 50:50, 70:30, 90:10 100:0. Fig. 9A shows an example of the restriction digest 
products of the different mixtures. The increasing ratio of the mutant resulted in brighter 
bands of 125bp and weaker bands of 90bp. For these experiments the loading of the gel was 
done such that same intensity range as used for patient samples was achieved, as could be 
judged from the DNA standard. From three independent experiments performed to calculate 
the fraction of mutant in the known mixtures, the results were summed up and are presented 
in Fig. 9B. These data evince an estimate of the deviations that could arise in our experiments 
due to errors in pipetting or band analysis by densitometry and curve fitting. The fraction of 
mutant determined for the above-mixtures of mutant and wild type plasmids were 0%, 
23.3±1.5%, 39.3±3.7%, 49±5.2%, 68±5.1%, 86.5±3.5% and 100% respectively. Therefore, 
during PCR, the mixed allelic templates were amplified in direct proportion to the 
stoichiometric fraction of each template. 
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Fig. 8. Experimental approach to minimize heteroduplex formation. (A) Schematic 
representation of restricton fragments produced by Nde II digestion of the wild type and 
mutant homoduplexes for mutation R723G. The 90bp fragment is produced exclusively by the 
wild type and the 125bp fragment is produced exclusively from the mutant. Formation of 
heteroduplexes between a wild type and mutant strand makes a restriction site to become 
refractory (grey arrows), thus producing a 125bp fragment also from the heteroduplex. (B) 
Reconditioning PCR to ascertain that the samples taken for quantification are in the 
exponential range of the reaction. For this particular example the samples were in the 
exponential range approximately until the 7
th
 cycle. The small error bars of the PCR product 
at a given cycle number are obtained from the averaging the intensities of the PCR product 
at different different exposure times. (C) A 3.5% agarose gel with restriction digests of 
R723G PCR products from the 3
rd
, 4
th
, 5
th
 and 6
th
 PCR cycle from the experiment shown in 
(B). The fraction of mutated !-MHC-mRNA is 70%, 67%, 63% and 63% for cycles 3, 4, 5 
and 6, respectively.  In case of heteroduplex formation, an increse of the relative amount of 
mutated !-MHC-mRNA would be expected due to the uncleaved 125bp fragment. Left four 
lanes, increasing volumes (6!l, 12!l, 15!l and 20!l, respectively) of Low DNA Mass Ladder; 
B: Blank; U: undigested 281bp PCR product. 
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4.2 Controls for heteroduplex formation 
Because our assays contain the wild type and the mutant templates differing only by a single 
nucleotide, heteroduplexes might form between the two kinds of strands under 
denaturation/reannealing conditions in the plateau phase of PCR. As an example, Fig. 8A 
depicts schematically for mutation R723G how heteroduplexes which may form during the 
plateau phase eliminate a restriction site in such a chimeric species. The elimination of the 
restriction site in this case for the enzyme NdeII impairs the ability of this enzyme to 
recognize its cognate sequence, which is now present only on one strand. Hence, a fragment 
of size 125bp which is derived from the heteroduplexes would co-migrate with the fragment 
of the same size derived from the mutant homoduplex species on agarose gels, resulting in an 
overestimation of the mutant species.  
In order to circumvent the problem of generation of heteroduplexes, we used an approach of 
a ‘reconditioning PCR’ whereby, the PCR products from a 35 cycles reaction were diluted 
and re-amplified from 1 to about 20 cycles for generation of a PCR curve (Fig. 8B). It is seen 
that the curve enables the determination of the exponential phase of the reaction i.e., in this 
case, from the 1st until at least the 7th cycle where the efficiency of the reaction is close to 2.  
The samples for quantification were taken from the exponential parts of the PCR curve (Fig. 
8C) e.g., 4th cycle. Since at the 4th cycle the intensity of the PCR product was not strong 
enough for detection on ethidium bromide agarose gels, the signal was intensified by pooling 
several aliquots collected after the 4th cycle, before performing the restriction digestion.  
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Fig. 9. Relative quantification of mutant and wild type fragments in defined mixtures of 
plasmids with R723G mutant and wild type sequences. (A) 3.5% agarose gel with NdeII 
restriction fragments of a 281bp PCR product (lane 1) amplified by the R723G primers. 
Lanes 2-8; restriction fragments of PCR products in plasmid mixtures with ratios of 20:80, 
40:60, 50:50, 70:30, 90:10, 100:0 and 0:100, respectively, of the mutant:wild type plasmids. 
Lane L; Equimolar DNA standard, lane B; blank. (B) Expected (circles) vs. measured 
(triangles) percentage of mutant PCR product in plasmid mixtures from three independent 
experiments. For the above-mentioned plasmid mixtures, the fraction of mutant we found was 
23.3±1.5%, 39.3±3.7%, 49±5.2%, 68±5.1%, 86.5±3.5%, 100% and 0% respectively. 
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Estimation of heteroduplex formation 
In addition, to further estimate the extent of the possible formation of heteroduplexes for 
mutation R723G in a reaction of 35 cycles, the mutant-specific 125bp fragment after the 
NdeII cleavage (Fig. 8A) was isolated and cloned into a vector. Sequence analysis in both 
forward and reverse orientations of 105 cloned fragments showed only two fragments to 
contain sequences that result from formation of heteroduplexes.  
Finding just 2 positives out of 105 samples, we put forward the question how reproducible 
this result is. If we repeat the experiments how sure can we be that we get a similar small 
number of positives. If we propose a confidence limit of 95% how large could the number of 
positives be? We calculated this using the binomial distribution. Given, the actually measured 
number of positives and sample size, the true fraction of positives lies in an interval from 0 to 
0.06 with 95% confidence. 
This actually means that with only 5% probability the fraction of positives measured could be 
more than 0.06. In our case this means that even by pushing the limits of PCR it is quite 
improbable that we get more than 6% heteroduplexes.  
 
4.3 Quantification of the relative amount of mutated !-MHC mRNA for 
the mutation R723G  
The ratio of mutated vs. wild type !-MHC-mRNA in the myocardium and M. soleus biopsies 
of one patient (H27, 57 years old) of a Catalan family (Enjuto et al., 2000) carrying the 
R723G mutation in the converter domain of !-MHC was quantified. Mutation R723G is 
caused by a c/g transversion in exon 20 of the MYH7 gene. Since this mutation neither 
creates not abolishes a restriction enzyme site, we used a mutagenic forward primer to create 
a cleavage site. Fig. 10A depicts a quantification from a soleus biopsy. On the agarose gel the 
restriction fragments of the cDNA from this patient are shown in lanes 2, 3, 4 and 5, 
respectively. The uppermost 156bp band is derived from, both the mutant and the wild type 
PCR products, the 125bp exclusively from the mutant and the 90bp exclusively from the wild 
type (c.f. Fig. 8A). A 35bp fragment, also produced by the digestion of the wild type PCR 
product is not visible, owing to its small size. Hence, the intensity of the 35bp fragment was 
excluded from our calculation of the proportion of mutant mRNA present in the heterozygous 
patient cDNA. The 156bp fragment served as an internal control in the calculations as it is 
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derived from both the wild type and the mutant PCR products. We calculated the ratio of 
IOD/bp values of the sum of 125bp fragment and 90bp fragment over the IOD/bp value of 
the 156bp fragment to ensure that this ratio was close to 1. 
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Fig. 10. Relative quantification of wild type and mutant !-MHC-mRNA for mutation R723G. 
(A) 3.5% agarose gel with restriction fragments (lanes 2-5) of a 281bp PCR product (lane 1) 
from the soleus muscle of patient H27. Restriction fragments were obtained after 
reconditioning PCR for 3, 4, 5 and 6 cycles respectively. Fragments are as depicted in Fig. 
8A. (156bp from mutant + wild type, 125bp from mutant and 90bp from wild type PCR 
products, respectively). L, equimolar DNA standard; B, blank. (B) Fraction of mutated 
mRNA in the myocardium and M. soleus of several patients of three families with mutation 
R723G. The fraction of mutated !-MHC-mRNA in the myocardium (m) of patient H27 was 
71.8±5.3% (n=12 restriction digests) and that in his soleus (s) muscle was 66.4±6.9% 
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(n=10). Patient H29 had 67.2±4.9% (n=28) of mutated !-MHC-mRNA in the myocardium 
(m). For other patients, H28 (n=7), H71 (n=16) and H72 (n=15) the fractions of mutated !-
MHC-mRNA in the soleus muscle (s) were 62±3.5%, 69.5±7.8% and 66.1±4.3%, 
respectively. 
 
We found that the fraction of mutated !-MHC-mRNA in the soleus muscle of patient H27 
was 66.4±6.9% (n=10 restriction digests) and in the anterior wall of the myocardium of this 
patient was 71.8±5.3% (n=12 restriction digests) (Fig. 10B). Thus, the fraction of mutated 
mRNA for the mutation R723G deviates clearly from the 50% expected for an autosomal 
dominant disorder. Yet this deviation is very similar for myocardium and soleus of the same 
patient. In H28 (50 years), the brother of H27, the fraction of mutated mRNA in the soleus 
muscle biopsy was 62±3.5% (n=7 restriction digests). We also analyzed soleus muscle 
samples from a younger patient (H71, 32 years) of the same family and found that the 
fraction of mutated !-MHC mRNA for this patient was 69.6±7.7% (n=16 restriction digests). 
A female patient, H29, with mutation R723G, from a second family, for whom only the 
myocardium samples were available, had 67.12±4.9% (n=28 restriction digests) mutated !-
MHC-mRNA in the left ventricle. In yet another younger patient, H72 (30 years old) from a 
third Catalan family, the soleus muscle had 66.1±4.3% (n=15 restriction digests) mutated !-
MHC-mRNA.  
The difference in expression of mutated !-MHC-mRNA in the two tissues of H27 is not 
significant (p=0.064). In addition, the expression level of mutated !-MHC-mRNA between 
the other patients is not significantly different (p$0.05), yet for H28 it is slightly lower 
(p=0.05) compared to H27 soleus.  For all these patients the wild type:mutant ratio of !-
MHC-mRNA deviates from the expected 50:50 ratio. The data further indicate that the 
expression of the mutated !-MHC-mRNA seems to be very similar among patients with this 
mutation, even when they are from different families. From the presented results of patient 
H27, and also from H29 in comparison to the soleus biopsies from the other patients with 
R723G, it can be inferred that the fraction of mutated !-MHC-mRNA in the slow skeletal 
muscle appears to be reflective of its expression in the myocardium.  
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4.4 Relative quantification of mutated mRNA for the mutations I736T, 
V606M and R719W in soleus biopsies 
To establish whether the deviation from 50:50 of the wild type and mutated mRNA was 
specific only to the above shown R723G mutation or whether it could be generalized for 
other HCM missense mutations in the coding region of the !-MHC gene, several other 
mutations were characterized with respect to the fraction of mutated !-MHC-mRNA 
expression in soleus muscle biopsies. The IOD/bp values for mutation V606M and R719W 
were obtained previously by I. Schulte (Schulte, 2001). These data are shown here to be able 
to compare all the patient data we have until now. 
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Fig. 11. Relative quantification of the fraction of mutated !-MHC-mRNA for different myosin 
point mutations. (A) Hpy8I restriction fragments for the quantification of mutated !-MHC-
mRNA for mutation I736T. The 378bp heterozygous PCR product yields 205bp, 149bp and 
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24bp fragments from the mutant and 354bp and 24bp fragments from the wild type PCR 
products, respectively. Lane 1, Low DNA Mass ladder; Lane 2, Blank; Lanes 3 and 5, 
undigested PCR product; Lane 4, digest of PCR product of control cDNA; Lane 6, restriction 
fragments of PCR product of heterozygous patient PCR product. The 24bp fragment is not 
seen on the agarose gel owing to its small size. (B) Restriction digestion of a 287bp 
heterozygous PCR product by restriction enzyme NlaIII for mutation V606M. The digestion 
yields a 180bp and 87bp and 20bp fragment from the cleavage of the mutant PCR product 
and a 267bp and 20bp fragment from the wild type PCR product. The faster migrating 20bp 
product is not seen on the gel. Lanes 1 and 2, Equimolar DNA standard; Lanes 3 and 4, 
restriction fragments of heterozygous patient PCR product. (C) Restriction fragments 
generated by MspI cleavage of a 378bp heterozygous PCR product for mutation R719W. The 
wild type PCR product upon cleavage furnishes 146bp, 123bp, 109bp fragments, while the 
mutant PCR product yields a 269bp and 109bp fragment. Lane 1, Equimolar DNA standard; 
Lane 2, Blank; Lanes 3 and 4; restriction fragments of heterozygous patient PCR product. 
The gel pictures in (B) and (C) were obtained by I. Schulte (2001) during her doctoral thesis 
in our laboratory (Molekular-und Zellphysiologie, MHH).  
 
I736T 
Total mRNA was isolated from soleus biopsies of three HCM-patients with the mutation 
I736T, all of them members of the same family, and !-MHC-mRNA was reverse transcribed 
into cDNA. The I736T mutation is caused by a T2293C transition in exon 20 of MYH7 gene, 
which creates a cleavage site for Hpy8I in the mutant sequence. The wild type sequence has 
no cleavage site for Hpy8I. However, to distinguish wild type and undigested PCR product, 
we had to ensure that the wild type product was cleaved too. Therefore a cleavage site was 
introduced into the PCR product by using a mutagen forward primer (Table 2). The 378bp 
PCR product when cleaved with Hpy8I, generates fragments of sizes 354bp and 24bp from 
the wild type sequence and of sizes 205bp, 149bp and 24bp respectively, from the mutant 
sequence. A restriction digest of !-MHC-cDNA obtained from the soleus muscle tissue of a 
heterozygous patient and a control individual along with the equimolar DNA ladder used for 
analysis is shown in Fig. 11A. For all three patients the fraction of mutated !-MHC-mRNA 
was calculated based on the IOD/bp ratio of the 205bp fragment of the mutant and the 
IOD/bp ratio of the 354bp fragment of the wild type, i.e., only the larger restriction digest 
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fragments which are clearly in the linear IOD/bp range of the equimolar ladder were used. 
The fraction of mutated !-MHC-mRNA was found to be 37,6 ± 4,2 % (n=22 restriction 
digests), 39,1 ± 4,1 % (n=20 restriction digests) and 38,6 ± 5,3 % (n=24 restriction digests) 
for patients H18, H19 and H20 respectively. Thus, for all the three patients a significant 
deviation in wild type:mutant ratio from 50:50 was observed. As an internal control for the 
restriction digest analyses of mutation I736T, we also calculated the ratio of the IOD/bp 
values for the mutant fragments of 149bp and 205bp. The ratio was 0.96±14, 1.01±0.09 and 
0.99±0.07 for patients H18, H19 and H20, respectively. This indicates in most cases, a rather 
small deviation from the expected 50:50 ratio of these control fragments. Altogether, the 
analysis of mutation I736T consolidates the observation also made for R723G, that within a 
family, i.e., for a given mutation, the expression of the mutated mRNA does not vary 
significantly. 
 
V606M 
For amplification of the cDNA from the patient with the V606M mutation forward primer 
FEx16 606, located within exon 16, and reverse primer RExon 16 II (Table 2), located at the 
splice junction between exons 16 and 17 were used (Schulte, 2001). These primers specified 
a 287bp PCR product. The V606M mutation is caused by a G1902A transition in exon 16, 
which creates an additional NlaIII cleavage site in the mutant sequence. NlaIII cleavage of a 
heterozygous 287bp PCR product, containing both wild type and mutant sequences, yields 
fragments of sizes 267bp, 180bp, 87bp and 20bp, respectively (Fig. 11B). The 20bp fragment 
is not seen due to its small size. The cleavage of the mutant PCR product yields two mutant-
specific fragments of 180bp and 87bp. Due to uncertainties in determination of the IOD 
values for the smaller and weaker 87bp fragment, we used the larger 180bp fragment to 
calculate the fraction of mutated !-MHC-mRNA in these biopsies. The relative amount of 
mutated !-MHC-mRNA in the M. soleus from the patient with mutation V606M on an 
average is 28±6% (n=40 restriction digests, IOD/bp values from I. Schulte). The uncertainties 
in analysis of the 87bp fragment of the mutant PCR product is also evident when we calculate 
as internal control the ratio of the 87bp fragment vs. the 180bp fragment which was 
0.85±0.17. The quite large deviation from the expected 1:1 ratio most likely is due to 
difficulties in measuring the intensity of the rather weak 87bp band. It is not expected to be 
due to incomplete digestion of the PCR product, since no undigested product and no cleavage 
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products of sizes other than the expected ones were found on the gels. Nevertheless, this 
mutation clearly shows a quite large deviation in expression of mutated:wild type !-MHC-
mRNA from the expected 50:50 ratio.  
 
 
R719W 
The R719W mutation results from a C2241T transition, which abolishes an MspI restriction 
site in the mutant sequence. From five soleus muscle pieces of the patient with mutation 
R719W, mRNA was isolated and separately reverse transcribed into cDNA (Schulte, 2001). 
Table 2 lists the primer pairs used to amplify the cDNA for this mutation. These primers 
specify a 378bp PCR product. Fig. 11C shows an example of a gel used for the analysis of 
mutation R719W. The MspI digest of the 378bp wild type PCR product resulted in three 
fragments of 146bp, 123bp and 109bp, as expected for a control individual. The heterozygous 
patient shows the three bands characteristic for the wild type allele, with an additional band 
of 269bp, which is characteristic for the mutant allele (Fig. 11C). The fraction of mutated 
PCR product and thus !-MHC-mRNA in the patient sample was calculated by taking the 
average of the almost identical IOD/bp values of the two wild type fragments (the 146bp 
fragment was 50.4±1.8% of the total amount of the 146bp and the 123bp fragment together) 
and the IOD/bp value of the 269bp fragment into account. For the patient with the mutation 
R719W, the fraction of the mutated  !-MHC-mRNA was 57.1 ± 5.4% mutant !-MHC 
mRNA (n=41 restriction digests, IOD/bp values from I. Schulte, 2001), and thus deviates 
somewhat from 50:50. As an internal control and to obtain an error estimate of the relative 
quantification for mutation R719W, we also calculated the ratio of the two wild type 
fragments of 123bp and 146bp on the gels. This yielded a ratio of 0.99±0.07, which is rather 
close to the expected 1:1 ratio. 
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Fig. 12. Fraction of mutated !-MHC-mRNA for different mutations in M. soleus (s) and 
myocardium (m) of different patients (H). All the mutations show a deviation from 50:50 in 
the ratio of mutated:wild type !-MHC-mRNA, although it might not be a significant deviation 
for R719W. Note that mutations I736T and R723G exhibit an intra- and/or inter-familial 
similarity in expression of mutated !-MHC-mRNA: all three patients with mutation I736T are 
siblings, patients with mutation R723G are either siblings (H27 and H28) or from the same 
family (H27, H28 and H71) or from different families. 
 
The data for all patients and samples are summarized in Fig. 12. This shows that the ratio of 
wild type and mutated  !-MHC-mRNA is, in general, quite variable between different 
mutations. It deviates in all patients from the expected 50:50 ratio and is similar between 
family members as exemplified by mutations R723G and I736T. 
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4.5 Fraction of mutated !-MHC-mRNA at single fiber level 
To address the question whether the deviation from a 50:50 ratio of mutated:wild type !-
MHC-mRNA is due to variable expression in individual muscle fibers, relative quantification 
of the mutant:wild type ratio in single soleus muscle fibers was attempted. 
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Fig. 13. Preliminary experiments on single fibers (F1-F11) of M. soleus from patient H27, 
carrying the mutation R723G, for quantification of the fraction of mutated !-MHC-mRNA. 
The fraction of mutated !-MHC-mRNA varies among individual fibers, in some fibers, the 
mutated mRNA is not expressed, in other fibers both the mutated and wild type !-MHC-
mRNAs are expressed to variable extents. For each fiber n=1. Only single analyses were 
possible with the small amount of cDNA obtained from each fiber. The number of fibers 
studied here is too small to be representative of the whole muscle tissue. 
 
In preliminary experiments on a soleus muscle biopsy of patient H27 with mutation R723G, 
eleven single fibers were analyzed in order to determine the fraction of mutated !-MHC-
mRNA in each of these fibers. It was observed that there is a variable expression of the 
mutated !-MHC-mRNA among individual fibers. Out of the 11 fibers that were analyzed 
Results 
56 
fibers 2, 4, 5, 7, 9 and 11 expressed 100% wild type !-MHC-mRNA. In the remaining five 
fibers the fraction of mutated !-MHC-mRNA varied considerably. 
Fibers 1, 3, 6, 8 and 10 had 52%, 41%, 66%, 16% and 33%, respectively, of the mutated !-
MHC-mRNA (Fig. 13). Yet, not enough fibers were studied until now for the result to 
represent the average of the whole muscle. Since the amount of mRNA extracted from each 
fiber was sufficient only for one experiment, data from repetitions were not obtained. These 
data seem to indicate a variation in expression of mutated !-MHC-mRNA in individual 
fibers. 
 
4.6 Pyrosequencing Experiments 
A pyrosequencing method was established for relative quantification of the mutated:wild type 
!-MHC-mRNA ratios in much smaller samples, possibly even in single cardiomyocytes.  
 
Control experiments with plasmids 
To test the pyrosequencing method, 281bp MYH7 wild type (C allele) and mutant (G allele) 
cDNA sequence including the site of mutation R723G (caused by a c/g transversion) were 
cloned into plasmids. Several defined mixtures with wild type:mutant ratios 100:0, 90:10, 
75:25, 50:50, 25:75, 10:90 and 0:100, respectively, were generated with these plasmids. Fig. 
14A (i-iii) illustrate the pyrograms for the plasmid mixtures of 100:0, 50:50 and 0:100 wild 
type:mutant composition. 
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Fig. 14A(i). Plasmid mixture: 100% WT 0% Mut 
 
 
 
Fig. 14A(ii). Plasmid mixture: 50% WT 50% Mut 
 
 
 
Fig. 14A(iii). Plasmid mixture: 0% WT 100% Mut 
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Fig. 14. (A) Pyrosequencing experiment with mixtures of plasmids carrying 281bp R723G 
wild type and mutant cDNA inserts. Pyrograms generated from defined mixtures of plasmids 
containing as inserts the 281bp wild type and mutant sequences for mutation R723G. On the 
y-axis is the peak height (amount of light generated), which is proportional to the amount of 
nucleotides incorporated into the growing DNA strand. The x-axis shows the nucleotide 
dispensation order. The peak (G) in the SNP detecting yellow area of the pyrogram of 100% 
wild type and 0% mutant in Fig. 14A(i) is not due to the mutation but due to another G, 
which is adjacent to the position of the SNP. The concentrations of both the wild type and 
mutant plasmids in the stock solution was 0.01ng/!l. (B) Plot of the expected vs. measured 
fractions of mutated !-MHC cDNA in plasmid mixtures (n=2). 
 
Fig. 14A(i) shows a 100:0 wild type vs. mutant pyrogram. Whereas, the peak for the C allele 
denotes 100% wild type, the peak of a similar height for the G allele comes from a G 
nucleotide towards the 3’ end of the SNP position.  Note how in the 50:50 pyrogram (shown 
as example in Fig. 14Aii), the peak height of the C allele decreases with the reduction in the 
fraction of the wild type plasmid and the G allele peak height increases due to the increase in 
the fraction of mutant plasmid in the plasmid mixture. The results of two such experiments 
are summed up in Fig. 14B, which gives an estimate of the error that could arise due to 
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pipetting or other experimental procedures. Plasmids differing by a single nucleotide (c/g) in 
their 275bp genomic DNA MYH7 inserts encompassing the site of the R723G mutation were 
also used for further control experiments.  
 
 
 
Fig. 15. Pyrosequencing experiments with mixtures of plasmids carrying 275bp MYH7 
genomic wild type and mutant sequences including the site of mutation R723G. Plot of 
expected vs. measured mutant insert in mixtures of plasmid containing the genomic sequence 
fragments including the site of mutation R723G. The plasmids were mixed in a wild 
type:mutant ratios of 100:0, 90:10, 75:25, 50:50, 25:75, 10:90 and 0:100%, respectively. The 
concentrations of the mutant as well as the wild type plasmids in the stock solution was 
0.0001ng/!l (n=4). 
 
The genomic wild type and mutant plasmids were also mixed in 100:0, 90:10, 75:25, 50:50, 
25:75, 10:90 and 0:100, respectively, and were subjected to pyrosequencing. The results of 4 
experiments are presented in Fig. 15. The genomic controls were necessary because we 
wanted to test whether the patient samples start deviating from 50:50 at the genomic level.  
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Pyrosequencing experiments with genomic DNA and cDNA 
 
Fig. 16(A). Pyrogram from healthy control (S.T.) 
 
 
 
Fig. 16(B). Pyrogram from H27 
 
 
Fig. 16. (A) Pyrosequencing experiments with genomic DNA of human samples. 
Pyrosequencing results of PCR products obtained from the genomic DNA extracted from 
whole blood of a healthy control. The wild type allele was 96.9% in this analysis. (B) 
Pyrogram generated from the PCR product obtained from genomic DNA in the myocardium 
muscle piece of H27, carrying the R723G mutation. The fractions of wild type and mutated 
alleles, respectively, were 57% and 43%.  
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Fig. 17(A). Pyrogram from healthy control H22 
 
 
 
Fig. 17(B). Pyrogram from healthy control H32 
 
 
Fig. 17. Pyrosequencing experiments with control cDNA. (A) cDNA from the soleus biopsy of 
a healthy individual H22 and (B) cDNA from a myocardial sample of a control individual, 
H32,  was subjected to PCR with the pyro cDNA primers listed in Table 3 and subsequently 
pyrosequenced. In both cases we found 100% wild type (C) and 0% mutant (G) allele. 
 
 
Pyrosequencing was performed on the PCR amplified genomic DNA from the myocardium 
of patient H27. We found a fraction of the wild type (C) allele of 57% and of the mutant (G) 
allele of 43% (Fig. 16B). Another pyrosequencing control experiment was carried out on 
genomic DNA of control individuals where DNA was extracted from whole blood and 
amplified with genomic primers listed in Table 3. As expected, the wild type (C) allele was 
96.9%, which is very close to 100%. Since more experiments were not performed on these 
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control samples, the estimation of error was not possible. Until now, relative quantification of 
cDNA from HCM patient samples with the pyrosequencing method has not been carried out 
successfully. Experimental conditions still need to be optimized. Instead, pyrosequencing 
experiments were successfully performed with the cDNAs from the soleus and myocardium, 
respectively, of two healthy controls H22 (Fig. 17A) and H32 (Fig. 17B). As expected the 
wild type (C) !-MHC-mRNA for both individuals was 100%. 
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5 Discussion 
In this study we found a variable expression of the allelic messages for different myosin head 
domain missense mutations in HCM. Autosomal dominant inheritance of HCM, when it is 
caused by single missense mutations in the cardiac myosin isoform, a priori implies that both 
mutated and wild type mRNA and protein are present at a 50:50 ratio in the muscle tissue of 
the patients heterozygous for the mutation. Yet, our results show that for four different !-
MHC head domain missense mutations, there is a deviation from the expected ratio in the !-
MHC-mRNA expression. The deviation from the expected ratio could arise due to several 
factors.  
 
Method of quantification. 
 Our assays employ co-amplification of wild type and mutated !-MHC-cDNAs in the same 
reaction followed by digestion of the PCR product with a restriction enzyme to differentiate 
between the wild type and the mutant PCR products. It is important to note that in the muscle 
tissues used for this study the mutated and the wild type !-MHC-mRNAs are co-expressed 
and would therefore have been subjected to the same experimental insults. Therefore, it is 
rather unlikely that the two species differing from one another by only a single nucleotide are 
differentially affected by the experimental protocols. For each mutation the mutant and wild 
type sequences were reverse-transcribed in a single tube, respectively, using a universal !-
MHC specific primer. Likewise, for each mutation the mutated and the wild type sequences 
were amplified using the same primer set (Table 2). Also, the restriction endonuclease used 
to differentiate between the mutated and wild type PCR products for a particular mutation 
was the same. 
One problem that would arise with this quantification method is the heteroduplex formation 
at high PCR cycle numbers. Heteroduplexes would yield faulty quantification results because 
a chimeric DNA molecule (consisting of one wild type strand and one mutant strand) makes a 
restriction site refractory to the restriction enzyme, causing a fragment of the digest (125bp, 
Fig. 8A) from the heteroduplexes to co-migrate with the fragment of the digest of the same 
size (125bp) from the homoduplex mutant DNA molecule. On the other hand sufficient PCR 
product is necessary for quantification of restriction digest products on the agarose gels. To 
circumvent the risk of erroneous quantification due to heteroduplex formation we established 
a reconditioning PCR method where PCR products from lower cycle numbers were pooled 
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for restriction digestion and gel analysis. Yet, even with the reconditioning PCR method 
(Thompson et al., 2002) to avoid heteroduplex formation, the deviation from 50:50 ratio was 
observed.  
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Fig. 18. Relative quantification of the fraction of mutated !-MHC-mRNA (grey) and mutated 
!-myosin (black) that is incorporated into the sarcomeres. The deviation from 50:50 occurs 
at both the protein and mRNA levels. The data also show that there is a close correlation 
between the expression of mutated !-MHC-mRNA and mutated !-myosin for a given 
mutation. One exception is V606M where the mRNA analyses was performed on a tissue 
prepared for histology and therefore the data are maybe not as reliable as the other 
mutations. The protein quantification data have been obtained by different people in our 
group and have mostly been published in the meantime. 
 
Quite importantly, our mRNA data are extensively reinforced by data of relative 
quantification of mutated vs. wild type myosin in the biopsies from the same patients, which 
was carried out in our laboratory on the same samples. It was observed that similar deviations 
from 50:50 also existed at the protein level. Fig. 18 shows a comparison of mRNA and 
protein data. For mutation V606M, the fraction of mutated myosin in the British patient was 
12±6% (Nier et al., 1999) and for another unrelated patient of American origin it was 13±2% 
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(unpublished data). Furthermore, the amount of mutated myosin in the muscle biopsy of the 
patient with mutation R719W was 54±7% (Kirschner et al., 2005) and that in patients with 
mutation I736T was 43±13%, 33±3% and 42±7% respectively (Becker et al., 2007). Protein 
quantifications for patients H27 and H28 with mutation R723G have shown 61.6±6.5 and 
62.4±6.9% of mutated myosin in the soleus biopsies of these patients (Becker et al., 2007), 
mutated myosin in the remaining biopsies has not been quantified yet. In all relative protein 
quantifications, the protein incorporated into the sarcomeres, which actually is functionally 
relevant, was determined. The fact that for nearly all mutations a very similar deviation from 
the 50:50 ratio was also found for !-MHC-mRNA and for myosin incorporated into the 
sarcomeres (Fig. 18), strongly supports that the deviation most likely is not due to 
heteroduplex formation or another experimental error. 
 
Inter- and intra-familial comparison of the mutated vs. wild type !-MHC-mRNA ratio 
Among the mutations studied, mutations I736T and R723G allowed us to analyze the intra-
familial expression of the mutated and the wild type alleles. For mutation I736T, the three 
patients H18, H19 and H20 siblings of the same Kyrgyz family have very similar fractions of 
mutated !-MHC-mRNA (average=38.4%) and of mutated myosin (average=39.3%). Patients 
H27, H28 and H71 belong to the same Catalan family and have similar fractions of mutated 
!-MHC-mRNA (average=66%) and mutated myosin at least for patients H27 and H28 
(average=62%). Protein quantification has not been done for H71, H72 and H29. For 
mutation R723G, it was also possible to analyze the inter-familial similarity in expression of 
the mutated !-MHC-mRNA. Patient H29, belongs to a second family and has approximately 
67% mutated !-MHC-mRNA in the myocardium. Patient H72 hailing from a third Catalan 
family has on an average 66% mutated !-MHC-mRNA in the soleus muscle (Fig. 12). For 
mutation V606M, two patients, one from a family in the UK and the other from an American 
family, without any known relationship were analyzed for the fraction of mutated myosin. 
The fraction of mutated protein in the sarcomeres of both these patients was very similar 
(12% and 13%, respectively, Fig. 18).  
 
The inter- and intra-familial similarity in expression of the mutated !-MHC-mRNA suggests 
that a specific pattern of expression for a given mutation is an inherent property of the 
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mutation itself, which would support the idea that the expression is regulated by an epigenetic 
mechanism. The similar expression levels of mutated !-MHC-mRNA in patients of different 
generations (H27 and H28 vs. H71 and H72 is in some contrast to the idea that at young age 
50% of the myocytes express wild type and 50% mutated protein, which then due to cell 
death, results in a deviation from 50:50. Our hypothesis is that the deviation from 50:50 is 
characteristic for each mutation and is most likely present already at very young age. 
 
Correlation of disease severity and the fraction of mutated !-MHC mRNA and !-
myosin 
HCM is characterized by marked heterogeneity in age of onset, genetic heterogeneity and also 
in disease manifestation (Rai et al., 2008; al., Bos et al., 2007, Arad et al., 2002). The 
heterogeneity is usually observed across families, but nevertheless intra-familial heterogeneity is 
also found (Keller et al., 2008). However, in our present study on the different !-myosin head 
domain mutations, although the number of patients studied was limited, a correlation is 
observed: the larger the fraction of mutated !-MHC-mRNA, the more severe is the disease 
expression. Therefore, the specific fraction of mutated !-MHC-mRNA and protein that is 
incorporated into the sarcomeres of these patients, for each mutation, may be a cause rather than 
an effect of the disease.  
Genotype-phenotype correlations have shown that mutation R719W is associated with a high 
risk of sudden death for the individuals carrying this mutation (Anan et al., 1994; Ackerman et 
al., 2002). We had one female British patient with mutation R719W. The fraction of mutated !-
MHC-mRNA in her slow soleus muscle fibers was approximately 57%. This patient was only 
22 years old when she had a cardiac arrest and received an ICD. Among the chief pathological 
features was the inter-ventricular septum thickness of 26 mm. Most likely both, the fraction of 
mutated myosin and the specific location and type of mutation contribute to the malignancy of 
the disease in this patient. For V606M, however, the situation is not so definitive. Patients from 
several kindreds with this mutation have a variable extent of ventricular hypertrophy but nearly 
normal survival; therefore it was considered a benign mutation (Watkins et al., 1992; Marian et 
al., 1995). However, there are also other reports for single kindreds where V606M mutation was 
found to cause a malignant HCM phenotype (Fananapazir et al., 1994, Semsarian et al., 1997; 
Havndrup et al., 2001). For the cases where the V606M mutation was malignant, it is not 
excluded that the fraction of mutated !-MHC-mRNA may be greater than 50%. Quantification 
of mutated vs. wild type ratio at protein and mRNA level in these families would be interesting 
to test this idea. Our hypothesis is that the expression level is characteristic for a given mutation, 
which would be a low level for mutation V606M. An alternative explanation for a malignant 
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phenotype with mutation V606M would be that there might have been an additional, as yet 
undetected mutation contributing to the severity of the disease. For mutation G584R where 
relative quantification was done only on protein level (Fig. 18), the fraction of mutated 
molecules is significantly less than 50%. The disease is manifested by mild symptoms. The 
three patients harboring I736T in the converter domain of the !-MHC show variable clinical 
symptoms with, most likely, a normal life expectancy. They were diagnosed with moderate left 
ventricular hypertrophy with pathological ECG and maximal septal wall thickness of 14, 18 and 
17 mm, respectively for H18, H19 and H20. These patients for whom the mutated !-MHC-
mRNA (38.4% on an average) and protein level (39.3% on an average) were less than 50%, 
were categorized as NYHA II group (Perrot et al., 2005).   
One of the most malignant mutations of this study is R723G. The fraction of mutated !-MHC-
mRNA for all the five patients (Fig. 12) is on an average 66.3%. The three male patients, H27, 
H28 and H71 belong to the same family. H27 and H28 had received an ICD after syncopal 
episodes. Subsequently, both H27 and H28 underwent heart transplantation. The female patient, 
H29, from another family had also received a heart transplant. From a third family, H72 had 
received an ICD.  All five patients H27, H28, H29, H71 and H72, at the time of biopsy were 
classified as NYHA classes III, II, IV, I and I respectively (Enjuto et al., 2000). It has to be 
mentioned though, that such severe heart failure is not the common patho-mechanism in HCM 
and is found only for some mutations. 
Nevertheless, based on our data we propose that it is not only the type and location of the 
mutation in the !-myosin and the functional changes they cause which affects the prognosis of 
HCM, but also the fraction of mutated !-MHC-mRNA and !-myosin may be an 
indicator/determinant of prognosis and survival.  
 
Possible mechanisms for deviation from 50:50 
Regarding the disease causing mechanism in HCM it has been demonstrated in different 
studies that the missense mutation carrying !-MHC is incorporated into the sarcomeres 
(Cuda et al., 1993; Nier et al., 1999) of cardiac and slow-twitch skeletal muscles and does not 
cause alterations in the structure and assembly of the thick filaments (Köhler et al., 2002). 
Thus, the unequal expression of mutated !-MHC vs. wild type does not cause 
haploinsufficiency. The mutations studied here apparently act in a dominant negative manner, 
inducing functional changes of the acto-myosin interactions and therefore, of the whole 
sarcomere. 
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Sequence analyses of the !-MHC gene with respect to the mutations described in this study 
have shown that for all the mutations, save V606M, cytosine is involved. Methylation of 
cytosines in the CpG dinucleotides plays a crucial role in the regulation of gene expression. 
There exists evidence that methylation of cytosines in the CpG dinucleotides in the open 
reading frames or coding sequences of a gene may also cause repression of expression 
through chromatin remodeling (Komura et al., 1995; Hisano et al., 2003). It is also possible 
that CpG methylation in the intragenic regions downstream of the promoter cause closed 
chromatin structures that result in a reduction in RNA Pol II elongation efficiency (Lorincz et 
al., 2004). However, the change in chromatin conformation alone, due to a single base 
substitution seems to be an unlikely cause of the observed deviations. It is possible that other 
cis- or trans-acting factors, in conjunction with the chromatin remodeling cause such 
deviations.  
So far mostly frameshift and nonsense mutations that result in premature termination codon 
have been described that affect the mRNA turnover by activating pathways that cause a 
decrease in the mutated mRNAs. It has been demonstrated for the hERG gene in the human 
Long-QT syndrome (Gong et al., 2007) as well as as for the !-globin gene (Kugler et al., 
1995) that such mutations indeed cause a reduction in the mutated mRNA by nonsense-
mediated mRNA decay. The cell has evolved different strategies to recognize and decay 
faulty mRNA. Mechanisms like mRNA surveillance causing the degradation of aberrant 
mRNAs have been described (Wilusz et al., 2001; Hilleren et al., 1999). However, for the 
mutations studied here, it is not clear how the mutated and wild type transcripts are 
differentiated and how missense mutations in the coding region of the !-MHC gene affect the 
stabilities of the two transcripts, especially when the mutations do not affect a splice site. 
One possibility to explain varying levels of mutated !-MHC-mRNA for the different 
mutations is a variable number of muscle fibers or myocytes containing the mutation. We 
have evidence from mechanical studies on individual soleus muscle fibers from HCM 
patients with mutations R723G (H27), I736T (H19) and R719W (H13) that a much larger 
functional variability vs. control exists for a given mutation from one fiber to another i.e., 
some fibers have Ca++ sensitivity like control fibers, whereas others show highly significant 
differences (Kirschner et al., 2005). Yet it is unclear how or why in each cell only one allele 
would be activated. 
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Variable expression of !-myosin from myocyte to myocyte 
The functional variability from fiber to fiber (Kirschner et al., 2005), however, suggests a 
variable expression and incorporation of the mutated !-MHC into the sarcomeres of the 
individual muscle fibers. Consistent with the mechanical studies, preliminary quantifications 
of the mutated vs. wild type !-MHC-mRNA ratios in single fibers with mutation R723G of 
patient H27 have shown a large variability in the expression of mutated !-MHC-mRNA from 
fiber to fiber (Fig. 13). However, since the soleus muscle fibers have multiple nuclei, it 
remains unclear whether both alleles are transcribed in each nucleus or whether wild type and 
mutant alleles are transcribed independently in different nuclei to cause the observed 
deviations in expression.  
Therefore, to address the question of variable expression of mutated vs. wild type !-MHC 
from myocyte to myocyte, relative quantification of !-MHC-mRNA in single 
cardiomyocytes, each of which is uninucleate, is necessary. As a first step towards relative 
quantification of the fraction of mutated !-MHC-mRNA in individual cardiomyocytes we 
have already established a pyrosequencing method. This was necessary because 
pyrosequencing requires much less cDNA and there is a chance that it can be applied even to 
single myocytes (Salk et al., 2006). However, also in pyrosequencing great care must be 
taken to ensure that non-specific PCR products, which could affect the relative quantification, 
are not generated.  
 
Hypothesis for development of myocyte disarray 
We propose that a variable incorporation of mutated !-MHC in the sarcomeres of each 
cardiomyocyte would cause a variable force generation in each myocyte, thereby resulting in 
functional imbalances, particularly among myocytes arranged in series, in the myocardium 
(Fig. 19). This might trigger development of myocyte disarray, which is characteristic for the 
HCM phenotype in many cases (Elliot and McKenna, 2004; Varnava et al, 2000).  
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Fig. 19. Hypothesis for the development of disarray and possibly hypertrophy observed in 
HCM caused by myosin mutations. In the uninucleate (blue) cardiomyocytes of heterozygous 
(Hz) patients, it is possible that either the wild type (WT; white), or mutated (Mut; black) or 
both alleles (grey) transcribe the !-MHC mRNA and would therefore possibly result in 
varying amounts of the wild type and mutated !-MHC in the contractile apparatus of 
individual cardiomyocytes. 
 
The model in Fig. 19 not only is able to explain why a deviation from 50:50 is observed in 
the expression of wild type vs. mutated !-MHC-mRNA, it also might provide a unifying 
mechanism at least for the development of typical HCM-symptoms such as disarray and 
maybe even hypertrophy in HCM caused by !-myosin mutations. When individual 
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cardiomyocytes contain varying amounts of the mutated !-myosin, which causes functional 
changes of the sarcomere (Köhler et al., 2002; Kirschner et al., 2005; Lankford et al., 1995), 
then this may result in imbalances of force generation and relaxation among the individual 
myocytes. Such functional imbalances among individual myocytes particularly when they are 
arranged in series could have at least two consequences: (1) it may disrupt the orderly 
alignment and cause myocyte disarray and apoptosis of weaker cells with connective tissue 
deposition (yellow) around the cells which is the key feature of HCM. (2) Variable force 
generation of neighboring myocytes might cause excessive stretch on some cells (while 
others may hyper-contract). Increased stretch could activate signaling cascades leading to 
myocyte hypertrophy, which according to current models can be induced by a stretch sensing 
mechanism located in the Z-line (Knöll et al., 2002; Pyle et al., 2004) or in transmembrane 
protein complexes (Brancaccio et al., 2003) of the cardiomyocytes. 
 
It would be of great interest for future studies to find out whether this as yet hypothetical 
mechanism would even provide a unifying mechanism for development of at least some 
aspects of the HCM phenotype also when HCM is caused by mutations in other sarcomeric 
proteins.     
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